[go: up one dir, main page]

US20050054645A1 - Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor - Google Patents

Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor Download PDF

Info

Publication number
US20050054645A1
US20050054645A1 US10/958,225 US95822504A US2005054645A1 US 20050054645 A1 US20050054645 A1 US 20050054645A1 US 95822504 A US95822504 A US 95822504A US 2005054645 A1 US2005054645 A1 US 2005054645A1
Authority
US
United States
Prior art keywords
hydroxy
pyrido
pyrazine
group
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/958,225
Other languages
English (en)
Inventor
Susumu Miyazaki
Susumu Katoh
Kaoru Adachi
Hirotaka Isoshima
Satoru Kobayashi
Yuji Matsuzaki
Wataru Watanabe
Kazunobu Yamataka
Shinichi Kiyonari
Shuichi Wamaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34197143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20050054645(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of US20050054645A1 publication Critical patent/US20050054645A1/en
Assigned to JAPAN TOBACCO INC. reassignment JAPAN TOBACCO INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: YAMATAKA, KAZUNOBU, KOBAYASHI, SATORU, ADACHI, KAORU, KATOH, SUSUMU, ISOSHIMA, HIROTAKA, MATSUZAKI, YUJI, MIYAZAKI, SUSUMU, WAMAKI, SHUICHI, KIYONARI, SHINICHI, WATANABE, WATARU
Priority to US11/255,605 priority Critical patent/US7211572B2/en
Priority to US11/783,270 priority patent/US20080161311A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present invention relates to a novel nitrogen-containing fused ring compound or a pharmaceutically acceptable salt thereof useful as an anti-HIV agent. Moreover, the present invention relates to novel use of a certain kind of nitrogen-containing fused ring compound or a pharmaceutically acceptable salt thereof as an anti-HIV agent. More specifically, the present invention relates to an anti-HIV agent containing a nitrogen-containing fused ring compound or a pharmaceutically acceptable salt thereof showing an anti-HIV action particularly based on an integrase inhibitory activity.
  • HIV Human Immunodeficiency Virus (type 1) belonging to retrovirus is a causative virus of AIDS (Acquired Immunodeficiency Syndrome).
  • HIV targets CD4 positive cell groups such as helper T cell, macrophage and dendritic cell and destroys these immunocompetent cells to cause immunodeficiency.
  • CD4 positive cell groups such as helper T cell, macrophage and dendritic cell and destroys these immunocompetent cells to cause immunodeficiency.
  • a pharmaceutical agent that eradicates HIV in a living organism or suppresses its growth is effective for the treatment or prophylaxis of AIDS.
  • HIV possesses a bimolecular RNA gene in a shell, and which is covered with an envelope protein.
  • the RNA codes for several enzymes (protease, reverse transcriptase, integrase etc.) characteristic of the virus and the like, and has translated reverse transcriptase and integrase in the core, as well as protease inside and outside the core.
  • DNA is transcribed by reverse transcriptase, and a full length double stranded DNA is produced.
  • the DNA moves into the core of the host cell and is incorporated by integrase into the DNA of the host cell.
  • the incorporated DNA is converted to an mRNA by polymerase of the host cell, from which mRNA various proteins necessary for forming a virus are synthesized by HIV protease and the like, and a virus particle is finally formed, which then undergoes budding and its release.
  • zidovudine, didanosine, lamivudine and the like have been already on the market as reverse transcriptase inhibitors, and indinavir, nelfinavir and the like as protease inhibitors.
  • a multiple drug combination therapy concurrently using these pharmaceutical agents has been employed.
  • a combined use of two reverse transcriptase inhibitors zidovudine and didanosine
  • a combined use of three agents of reverse transcriptase inhibitors zidovudine and lamivudine
  • a protease inhibitor nelfinavir
  • Such multiple drug combination therapy is becoming a mainstream of AIDS therapy (Folia Pharmacologica Japonica, 118, 131-134, 2001).
  • WO01/96283 describes, as an anti-HIV agent having an integrase inhibitory activity, the following compound [A] (see WO01/96283, p. 176, compound 70).
  • WO03/016266 describes the following compound [B] and the like having an integrase inhibitory activity (see WO03/016266, p. 159, Example Nos. 3-17).
  • WO01/95905 describes the following compound [C] and the like, as an anti-HIV agent having an integrase inhibitory activity (see WO01/95905, p. 109, Example E-2).
  • WO03/047564 describes the following compound [D] and the like, as an anti-HIV agent having an integrase inhibitory activity (see WO03/047564, p. 73, Example 11).
  • WO02/30930 and WO02/55079 describe, as an anti-HIV agent having an integrase inhibitory activity, the following compounds [E], [F] and the like, respectively (see WO02/30930, p. 171, Example 1; WO02/55079, p. 79, Example 1). WO02/30426, WO02/30931 and WO02/36734 also disclose similar compounds.
  • WO03/031413 describes, as an anti-HIV agent having an integrase inhibitory activity, the following compound [G] and the like (see WO03/031413, p. 21, compound 8).
  • WO03/035076 and WO03/035077 describe, as an anti-HIV agent having an integrase inhibitory activity, the following compounds [H], [i] and the like (WO03/035076, p. 188, Example 1; WO03/035077, p. 146, Example 22).
  • WO2004/24078 describe, as an anti-HIV agent having an integrase inhibitory activity, the following compound [J] and the like.
  • This publication describes the following formula as the formula (I) of claim 1 and a tautomer thereof.
  • the compound described in this publication is clearly different from the compound of the present invention in that a hydroxyl group or a carbonyl group is essential at a position corresponding to the position of R y1 for Y 2 in the formula [I] of the nitrogen-containing fused ring compound of the present invention.
  • this publication does not suggest a compound free of a hydroxyl group or a carbonyl group at said position.
  • a production method of the compound of the formula (I) is disclosed in this publication from page 46 to page 113, but the production method concretely disclosed here cannot produce a nitrogen-containing fused ring compound encompassed in the present invention, and a concrete production method of this compound is not referred to at all.
  • an anti-HIV agent is effective for the prophylaxis of the onset of AIDS and the treatment thereof, and particularly a compound having an integrase inhibitory action can provide an effective anti-HIV agent.
  • the present inventors have conducted intensive studies in an attempt to find a compound having an anti-HIV action, particularly a compound having an integrase inhibitory action, and completed the present invention.
  • the present invention is as shown in the following [1] to [38].
  • the compound of the present invention can be a pharmaceutical agent effective for the prophylaxis or treatment of AIDS, as an anti-HIV agent having an HIV integrase inhibitory activity.
  • an anti-HIV agent having an HIV integrase inhibitory activity.
  • the compound can be a more effective anti-HIV agent.
  • the compound since the compound has an integrase-specific high inhibitory activity, it can be a pharmaceutical agent safe on the human body, which is associated with a fewer side effects.
  • the “bond” means a direct connection and in the case of N—Z—Ph, for example, when Z is a “bond”, it means N—Ph.
  • halogen atom is a fluorine atom, a chlorine atom, a bromine atom or an iodine atom, and is preferably a fluorine atom, a chlorine atom or a bromine atom.
  • group A it is more preferably a fluorine atom
  • group B it is more preferably a fluorine atom or a chlorine atom
  • group C it is more preferably a bromine atom.
  • the “C1-6 alkyl group” is a linear or branched chain alkyl group having 1 to 6 carbon atoms, and preferably a linear or branched chain alkyl group having 1 to 4 carbon atoms. Specifically, methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, isopentyl group, tert-pentyl group, hexyl group and the like can be mentioned.
  • R 6 , R b2 , R b3 , R b4 , R b5 or R b6 is preferably a methyl group for R 6 , R b2 , R b3 , R b4 , R b5 or R b6 , preferably a methyl group, a propyl group or an isopropyl group for R b1 , and preferably a methyl group, an ethyl group or a tert-butyl group for group B.
  • the “C1-7 alkyl group” is a linear or branched chain alkyl group having 1 to 7 carbon atoms, and is preferably a linear or branched chain alkyl group having 1 to 4 carbon atoms. Specifically, methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, isopentyl group, tert-pentyl group, hexyl group, 1-isopropyl-2-methylpropyl group and the like can be mentioned.
  • the “C2-6 alkenyl group” is a linear or branched chain alkenyl group having 2 to 6 carbon atoms. Specifically, vinyl group, allyl group, 1-propenyl group, isopropenyl group, 2-methyl-1-propenyl group, 1-butenyl group, 2-butenyl group, 1,3-butadienyl group, 3-methyl-2-butenyl group, 4-methyl-2-pentenyl group, 4-methyl-3-pentenyl group, 1-methyl-2-butenyl group and the like can be mentioned.
  • the “C2-6 alkynyl group” is a linear or branched chain alkynyl group having 2 to 6 carbon atoms. Specifically, ethynyl group, 1-propynyl group, 2-propynyl group, 3-butynyl group and the like can be mentioned.
  • the “C1-6 alkylene” is a linear or branched chain alkylene having 1 to 6 carbon atoms and methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, propylene, —CH(CH 3 )—, C(CH 3 ) 2 —, —CH(CH 3 )—(CH 2 ) 2 — and the like can be mentioned.
  • it is methylene, ethylene, trimethylene or tetramethylene, and more preferably methylene.
  • the “C2-6 alkenylene” is a linear or branched chain alkenylene having 2 to 6 carbon atoms and vinylene, propenylene, 1-butenylene, 1,3-butadienylene, —CH(CH 3 )—CH ⁇ CH— and the like can be mentioned. Preferably, it is propenylene.
  • haloC1-6 alkyl group is the above-defined “C1-6 alkyl group” substituted by the above-defined “halogen atom”, and preferably it is a haloalkyl group wherein its alkyl moiety is a linear or branched chain alkyl group having 1 to 4 carbon atoms.
  • fluoromethyl group, difluoromethyl group, trifluoromethyl group, bromomethyl group, chloromethyl group, 1,2-dichloroethyl group, 2,2-dichloroethyl group, 2,2,2-trifluoroethyl group and the like can be mentioned.
  • it is trifluoromethyl group.
  • the “C1-6 alkyloxy group” is an alkyl-oxy group wherein its alkyl moiety is the above-defined “C1-6 alkyl group”, and preferably an alkyl-oxy group wherein its alkyl moiety is a linear or branched chain alkyl group having 1 to 4 carbon atoms. Specifically, methoxy group, ethoxy group, propoxy group, isopropyloxy group, butoxy group, isobutyloxy group, tert-butyloxy group, pentyloxy group, hexyloxy group and the like can be mentioned.
  • the “C6-14 aryl group” is an aromatic hydrocarbon group having 6 to 14 carbon atoms. Specifically, phenyl group, naphthyl group, anthryl group, indenyl group, azulenyl group, fluorenyl group, phenanthryl group and the like can be mentioned, with preference given to phenyl group.
  • the “C6-14 aryloxy group” is an aryl-oxy group wherein its aryl moiety is the above-defined “C6-14 aryl group”. Specifically, phenoxy group, naphthyloxy group, anthryloxy group, indenyloxy group, azulenyloxy group, fluorenyloxy group, phenanthryloxy group and the like can be mentioned, with preference given to phenoxy group.
  • the “C6-14 aryl C1-6 alkyl group” is an aryl-alkyl group wherein its alkyl moiety is the above-defined “C1-6 alkyl group” and its aryl moiety is the above-defined “C6-14 aryl group”.
  • it is an aryl-alkyl group wherein its alkyl moiety is a linear or branched chain alkyl group having 1 to 4 carbon atoms and its aryl moiety is phenyl group.
  • benzyl group, phenethyl group, 3-phenylpropyl group, 2-phenylpropyl group, 4-phenylbutyl group and the like can be mentioned.
  • the “C6-14 aryl C1-6 alkyloxy group” is an aryl-alkyl-oxy group wherein its C6-14 aryl C1-6 alkyl moiety is the above-defined “C6-14 aryl C1-6 alkyl group”.
  • it is an aryl-alkyl-oxy group wherein its alkyl moiety is a linear or branched chain alkyl group having 1 to 4 carbon atoms and its aryl moiety is phenyl group.
  • benzyloxy group, phenethyloxy group, 3-phenylpropyloxy group, 2-phenylpropyloxy group, 4-phenylbutyloxy group and the like can be mentioned.
  • the “C6-14 aryl C1-6 alkyloxycarbonyl group” is an aryl-alkyl-oxy-carbonyl group wherein its C6-14 aryl C1-6 alkyl moiety is the above-defined “C6-14 aryl C1-6 alkyl group”.
  • it is an aryl-alkyl-oxy-carbonyl group wherein its alkyl moiety is a linear or branched chain alkyl group having 1 to 4 carbon atoms and its aryl moiety is phenyl group.
  • benzyloxycarbonyl group phenethyloxycarbonyl group, 3-phenylpropyloxycarbonyl group, 2-phenylpropyloxycarbonyl group, 4-phenylbutyloxycarbonyl group and the like can be mentioned.
  • It is preferably benzyloxycarbonyl group.
  • the “C6-14 arylcarbonyl group” is an aryl-carbonyl group wherein its aryl moiety is the above-defined “C6-14 aryl group”. Specifically, benzoyl group, 1-naphthoyl group, 2-naphthoyl group, anthrylcarbonyl group, indenylcarbonyl group, azulenylcarbonyl group, fluorenylcarbonyl group, phenanthrylcarbonyl group and the like can be mentioned, with preference given to benzoyl group.
  • the “C3-10 carbon ring group” is a saturated or unsaturated cyclic hydrocarbon group having 3 to 10 carbon atoms and means aryl group, cycloalkyl group, cycloalkenyl group, or a fused ring thereof.
  • aryl group phenyl group, naphthyl group, pentalenyl group, azulenyl group and the like can be specifically mentioned. It is preferably phenyl group or naphthyl group, and more preferably phenyl group.
  • cycloalkyl group cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group, cyclooctyl group, adamantyl group, norbornanyl group and the like can be specifically mentioned. It preferably includes cyclopentyl group, cyclohexyl group and cycloheptyl group, and particularly preferably includes cyclopentyl group and cyclohexyl group.
  • the “cycloalkenyl group” contains at least one, preferably 1 or 2, double bonds. Specifically, cyclopropenyl group, cyclobutenyl group, cyclopentenyl group, cyclopentadienyl group, cyclohexenyl group (2,4-cyclohexadien-1-yl group, 2,5-cyclohexadien-1-yl group etc.), cycloheptenyl group and cyclooctenyl group and the like can be mentioned.
  • it is a fused ring of phenyl group and other ring, such as indenyl group, indanyl group, 1,4-dihydronaphthyl group, 1,2,3,4-tetrahydronaphthyl group and the like.
  • heteroaryl group is a 5 or 6-membered heteroaryl group containing, as a ring-constituting atom, besides the carbon atom, at least one hetero atom selected from nitrogen atom, oxygen atom and sulfur atom.
  • heterocyclic group is a saturated or unsaturated (including partially unsaturated and completely unsaturated) monocyclic 5-membered or 6-membered heterocycle containing, besides carbon atom, at least 1, preferably 1 to 4, hetero atoms selected from nitrogen atom, oxygen atom and sulfur atom, or a fused ring of such heterocycles, or a fused ring of a carbon ring selected from benzene, cyclopentane and cyclohexane and the above-defined heterocycle.
  • pyrrolidinyl group tetrahydrofuryl group, tetrahydrothienyl group, imidazolidinyl group, pyrazolidinyl group, 1,3-dioxolanyl group, 1,3-oxathiolanyl group, oxazolidinyl group, thiazolidinyl group, piperidinyl group, piperazinyl group, tetrahydropyranyl group, tetrahydrothiopyranyl group, dioxanyl group, morpholinyl group, thiomorpholinyl group, 3-hydroxypyrrolidinyl group, 2-oxopyrrolidinyl group, 3-oxopyrrolidinyl group, 2-oxopiperidinyl group, 4-oxopiperidinyl group, 2,6-dioxopiperidinyl group and the like can be mentioned.
  • it is pyrrolidinyl group, tetrahydrofuryl group, te
  • indolyl group isoindolyl group, 1,3-dihydro-1,3-dioxoisoindolyl group, benzimidazolyl group, indazolyl group, benzothiazolyl group, benzofuranyl group, isobenzofuranyl group, indolizinyl group, quinolyl group, isoquinolyl group, 1,2-dihydro-2-oxoquinolyl group, quinazolinyl group, quinoxalinyl group, cinnolinyl group, phthalazinyl group, quinolizinyl group, pyrinyl group, pteridinyl group, indolinyl group, isoindolinyl group, 5,6,7,8-tetrahydroquinolyl group, 1,2,3,4-tetrahydroquinolyl group, 2-oxo-1,2,3,4-tetrahydroquinolyl group, 1,3
  • it is indolyl group, benzofuranyl group, quinolyl group, benzothiazolyl group, 1,2,3,4-tetrahydroquinolyl group, 1,3-benzodidxolyl group or 1,2,4-benzotriazinyl group.
  • heterocyclic group that substitutes C1-7 alkyl group, C1-6 alkyl moiety, C2-6 alkenyl group and C2-6 alkynyl group of group C is preferably a 2-oxopyrrolidin-1-yl group.
  • the “C3-8 cycloalkyl group” is a cycloalkyl group having 3 to 8 carbon atoms, and is specifically cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group or cyclooctyl group.
  • R c7 in group C preferred is a cyclopentyl group.
  • the “C3-8 cycloalkyl C1-6 alkyl group” is a cycloalkyl-alkyl group wherein the above-defined “C1-6 alkyl group” is substituted by the above-defined “C3-8 cycloalkyl group”.
  • the C1-6 alkyl moiety is preferably a linear alkyl group having 1 to 4 carbon atoms, and as C3-8 cycloalkyl, preferred are cyclopropyl group, cyclobutyl group, cyclopentyl group and cyclohexyl group.
  • C3-8 cycloalkyl C1-6 alkyl group cyclopropylmethyl group, cyclobutylmethyl group, cyclopentylmethyl group, cyclohexylmethyl group, 2-cyclohexylethyl group, 3-cyclohexylpropyl group and the like can be specifically mentioned.
  • C1-6 alkylsulfonyl group is an alkyl-sulfonyl group wherein its C1-6 alkyl moiety is the above-defined “C1-6 alkyl group”, preferably a linear or branched chain alkyl group having 1 to 4 carbon atoms.
  • methylsulfonyl group, ethylsulfonyl group, propylsulfonyl group, isopropylsulfonyl group, butylsulfonyl group, isobutylsulfonyl group, sec-butylsulfonyl group, tert-butylsulfonyl group, pentylsulfonyl group, isopentylsulfonyl group, tert-pentylsulfonyl group, hexylsulfonyl group and the like can be mentioned.
  • di(C1-6 alkyl)amino group is a di(alkyl)-amino group wherein its C1-6 alkyl moiety is the above-defined “C1-6 alkyl group”, preferably a linear or branched chain alkyl group having 1 to 4 carbon atoms.
  • dimethylamino group, diethylamino group, dipropylamino group, diisopropylamino group, N-ethyl-N-methylamino group, N-isopropyl-N-methylamino group and the like can be mentioned.
  • C1-6 alkylcarbonylamino group is an alkyl-carbonyl-amino group wherein its C1-6 alkyl moiety is the above-defined “C1-6 alkyl group”, and preferably a linear or branched chain alkyl group having 1 to 4 carbon atoms.
  • acetylamino group acetylamino group, propionylamino group, butyrylamino group, isobutyrylamino group, pivaloylamino group and the like can be mentioned.
  • C1-6 alkylcarbonyloxy group optionally substituted by halogen atom(s) is an alkyl-carbonyl-oxy group wherein its C1-6 alkyl moiety is the above-defined “C1-6 alkyl group”, which is optionally substituted by the above-defined “halogen atom”. It includes unsubstituted C1-6 alkylcarbonyloxy group, and is preferably one wherein its alkyl moiety is a linear or branched chain alkyl group having 1 to 4 carbon atoms.
  • the halogen atom is preferably a fluorine atom.
  • acetyloxy group, propionyloxy group, butyryloxy group, isobutyryloxy group, pivaloyloxy group, fluoromethylcarbonyloxy group, trifluoromethylcarbonyloxy group, 2,2,2-trifluoroethylcarbonyloxy group can be mentioned.
  • the “C6-14 aryl group optionally substituted by 1 to 3 substituent(s) selected from the group consisting of halogen atom, C1-6 alkyl group, C1-6 alkylsulfonyl group, di(C1-6 alkyl)amino group and C1-6 alkylcarbonylamino group” is the above-defined “C6-14 aryl group”, preferably a phenyl group, which is optionally substituted by 1 to 3 substituent(s) selected from the group consisting of the above-defined “halogen atom”, the above-defined “C1-6 alkyl group”, the above-defined “C1-6 alkylsulfonyl group”, the above-defined “di(C1-6 alkyl)amino group” and the above-defined “C1-6 alkylcarbonylamino group”, and includes unsubstituted aryl group.
  • C6-14 aryl group optionally substituted by 1 to 3 substituent(s) selected from the group consisting of halogen atom, C1-6 alkyl group, C1-6 alkylsulfonyl group, di(C1-6 alkyl)amino group and C1-6 alkylcarbonylamino group”, phenyl group, 2-fluorophenyl group, 3-fluorophenyl group, 4-fluorophenyl group, 4-chlorophenyl group, 4-bromophenyl group, 2,4-difluorophenyl group, 3,5-dichlorophenyl group, 4-methylphenyl group, 4-isopropylphenyl group, 4-tert-butylphenyl group, 4-dimethylaminophenyl group, 4-methylsulfonylphenyl group, 4-acetylaminophenyl group and the like can be specifically mentioned.
  • substituent(s) selected from the group consisting of halogen atom, C1-6 alkyl group,
  • It is preferably phenyl group, 2-fluorophenyl group, 4-fluorophenyl group, 4-tert-butylphenyl group, 4-dimethylaminophenyl group, 4-methylsulfonylphenyl group or 4-acetylaminophenyl group for group A.
  • heterocyclic group optionally substituted by C1-6 alkyloxy group is the above-defined “heterocyclic group”, which is optionally substituted by the above-defined “C1-6 alkyloxy group”, and includes unsubstituted heterocyclic group.
  • It is preferably a 5-membered or 6-membered monocyclic heterocyclic group.
  • heterocyclic group optionally substituted by C1-6 alkyloxy group pyrrolidinyl group, piperidinyl group, piperazinyl group, morpholinyl group, pyrrolyl group, furyl group, imidazolyl group, pyrazolyl group, 1,2,4-triazolyl group, tetrazolyl group, pyridyl group, pyrimidinyl group, pyrazinyl group, pyridazinyl group, 3-methoxypyridin-2-yl group, 6-methoxypyridin-2-yl group, 5-isopropyloxypyridin-3-yl group and 4-methoxypyrimidin-2-yl group and the like can be specifically mentioned.
  • group A is the following substituent group, in which R a1 , R a2 , R a3 and R a4 are each independently a hydrogen atom or the above-defined “C1-6 alkyl group”: the above-defined “halogen atom”, cyano group,
  • the “C1-6 alkyl group optionally substituted by 1 to 3 substituent(s) selected from group A” is the above-defined “C1-6 alkyl group”, which is optionally substituted by 1 to 3 substituent(s) selected from the above-defined “group A”, and includes unsubstituted alkyl group.
  • It is preferably methyl group, ethyl group, propyl group or pentyl group, particularly preferably methyl group or pentyl group, for R 1 .
  • the “C1-7 alkyl group optionally substituted by 1 to 3 substituent(s) selected from group A” is the above-defined “C1-7 alkyl group”, which is optionally substituted by 1 to 3 substituent(s) selected from “group A”, and includes unsubstituted alkyl group.
  • methyl group for R 2 It is preferably a methyl group for R 2 .
  • group C preferred are methyl group, ethyl group, propyl group, isobutyl group, isopropyl group, butyl group, isobutyl group, tert-butyl group, cyanomethyl group, hydroxymethyl group, 2-hydroxyethyl group, 1-hydroxyethyl group, 3-hydroxypropyl group, 1-hydroxypropyl group, 1-hydroxy-2-methylpropyl group, methoxymethyl group, isopropyloxymethyl group, isobutyloxymethyl group, 2,2-dimethylpropyl group, 2,2-dimethyl-1-hydroxypropyl group, 3,3-dimethyl-2-hydroxybutyl group, carboxymethyl group, methoxycarbonylmethyl group, methylcarbamoylmethyl group, dimethylcarbamoylmethyl group, methylsulfanylmethyl group, 2-(methylsulfanyl)ethyl group, methylsul
  • the “C2-6 alkenyl group optionally substituted by 1 to 3 substituent(s) selected from-group A” is the above-defined “C2-6 alkenyl group”, which is optionally substituted by 1 to 3 substituent(s) selected from “group A”, and includes unsubstituted alkenyl group.
  • vinyl group, allyl group, 1-propenyl group, isopropenyl group, 2-methyl-1-propenyl group, 1-butenyl group, 2-butenyl group, 1,3-butadienyl group, 3-methyl-2-butenyl group, 4-methyl-2-pentenyl group, 4-methyl-3-pentenyl group, 1-methyl-2-butenyl group, carboxyvinyl group, carbamoylvinyl group and the like can be mentioned.
  • the “C2-6 alkynyl group optionally substituted by 1 to 3 substituent(s) selected from group A” is the above-defined “C2-6 alkynyl group”, which is optionally substituted by 1 to 3 substituent(s) selected from “group A”, and includes unsubstituted alkynyl group.
  • ethynyl group 1-propynyl group, 2-propynyl group, 3-butynyl group, carboxyethynyl group, carbamoylethynyl group and the like can be mentioned.
  • the “group B” is a group selected from the following substituent group, in which R b1 , R b2 , R b3 , R b4 , R b5 and R b6 are each independently a hydrogen atom or the above-defined “C1-6 alkyl group”: the above-defined “halogen atom”, cyano group, the above-defined “C1-6 alkyl group”, the above-defined “haloC1-6 alkyl group”,
  • the “C3-10 carbon ring group optionally substituted by 1 to 3 substituent(s) selected from group B” is the above-defined “C3-10 carbon ring group”, preferably a phenyl group, which is optionally substituted by 1 to 3 substituent(s) selected from the above-defined “group C”, and includes unsubstituted C3-10 carbon ring group.
  • the ring D for R 1 is preferably phenyl group, 2-fluorophenyl group, 3-fluorophenyl group, 4-fluorophenyl group, 3,4-difluorophenyl group, 2-chlorophenyl group, 3-chlorophenyl group, 4-chlorophenyl group, 3-bromophenyl group, 4-bromophenyl group, 2,3-dichlorophenyl group, 2,6-dichlorophenyl group, 3,4-dichlorophenyl group, 3,5-dichlorophenyl group, 3-chloro-2-fluorophenyl group, 4-chloro-3-fluorophenyl group, 2-chloro-6-fluorophenyl group, 3-trifluoromethylphenyl group, 3-methoxyphenyl group, 3-chloro-2-hydroxyphenyl group, 3-chloro-2-methoxyphenyl group, 3-chloro-4-methoxyphenyl group, 3-chloro
  • heterocyclic group optionally substituted by 1 to 3 substituent(s) selected from group B is the above-defined “heterocyclic group”, which is optionally substituted by 1 to 3 substituent(s) selected from the above-defined “group C”, and includes unsubstituted heterocyclic group.
  • C6-14 aryl group optionally substituted by 1 to 3 substituent(s) selected from group B is the above-defined “C6-14 aryl group”, which is optionally substituted by 1 to 3 substituent(s) selected from the above-defined “group B”, and includes unsubstituted C6-14 aryl group.
  • It is preferably phenyl group, 2-fluorophenyl group, 2-ethylphenyl group, 2,6-dimethylphenyl group, 2-chlorophenyl group, 3-chlorophenyl group, 4-chlorophenyl group, 2-methoxyphenyl group, 3-methoxyphenyl group, 4-methoxyphenyl group, 2-hydroxyphenyl group, 3-hydroxyphenyl group, 4-hydroxyphenyl group or 2-trifluoromethylphenyl group for group C.
  • heteroaryl group optionally substituted by 1 to 3 substituent(s) selected from group B is the above-defined “heteroaryl group”, which is optionally substituted by 1 to 3 substituent(s) selected from the above-defined “group B”, and includes unsubstituted heteroaryl group.
  • 2-imidazolyl group 5-methylpyrazol-3-yl group, 5-methylisoxazol-3-yl group, 2-thiazolyl group, 1,2,4-triazol-3-yl group, 5-methyl-1,2,4-triazol-3-yl group, 5-ethyl-1,2,4-triazol-3-yl group, 1-ethyl-1,2,4-triazol-3-yl group, 1,5-dimethyl-1,2,4-triazol-3-yl group, 4-methyl-1,2,4-triazol-3-yl group, 4-ethyl-1,2,4-triazol-3-yl group, 5-tetrazolyl group, 5-ethyl-1,2,4-oxadiazol-3-yl group, 5-ethyl-1,3,4-oxadiazol-2-yl group, 2-pyridyl group, 4-methoxypyridin-2-yl group, 6-methylpyridin-2-yl group, 2-pyrimidinyl group, 4-pyrimidimid
  • the “group C” is a group selected from the following substituent group:
  • R c1 , R c2 , R c3 , R c4 , R c5 , R c6 , R c7 , R c8 , R c9 , R c10 , R c11 , R c12 , R c13 , R c14 , R c15 , R c16 , R c17 , R c18 and R c19 are each independently
  • the C1-7 alkyl group, C1-6 alkyl moiety, C2-6 alkenyl group and C2-6 alkynyl group of the above-mentioned group C are optionally substituted by 1 to 3 substituent(s) selected from the above-mentioned group A, or a nitrogen-containing heterocyclic group optionally containing a carbonyl moiety, and specifically includes the above-defined “C1-7 alkyl group optionally substituted by 1 to 3 substituent(s) selected from group A”, the above-defined “C2-6 alkenyl group optionally substituted by 1 to 3 substituent(s) selected from group A”, the above-defined “C2-6 alkynyl group optionally substituted by 1 to 3 substituent(s) selected from group A” and an oxy group substituted by the above-defined “C1-6 alkyl group optionally substituted by 1 to 3 substituent(s) selected from group A”.
  • the C6-14 aryl group, C6-14 aryl moiety and heterocyclic group of the above-mentioned group C are optionally substituted by 1 to 3 substituent(s) selected from the above-mentioned group B and specifically include the above-defined “C6-14 aryl group optionally substituted by 1 to 3 substituent(s) selected from group B”, the above-defined “heterocyclic group optionally substituted by 1 to 3 substituent(s) selected from group B”, the above-defined “C1-6 alkyl group” substituted by the above-defined “C6-14 aryl group optionally substituted by 1 to 3 substituent(s) selected from group B”, the above-defined “C1-6 alkyloxy group” substituted by the above-defined “C6-14 aryl group optionally substituted by 1 to 3 substituent(s) selected from group B”, and a carbonyl group substituted by the “C6-14 aryl group optionally substituted by 1 to 3 substituent(s) selected from group B”.
  • the “C6-14 aryl C1-6 alkyl group” of the above-mentioned group C includes a “C1-6 alkyl group” substituted by the above-defined “C6-14 aryl group optionally substituted by 1 to 3 substituent(s) selected from group B”, wherein the alkyl group moiety is substituted by 1 to 3 substituent(s) selected from the above-defined “group A”, and specifically, carbamoylphenylmethyl group, 1-carboxy-2-phenylethyl group, 1-hydroxymethyl-2-phenylethyl group, 1-carboxymethyl-2-phenylethyl group, 1-benzyloxycarbonyl-2-phenylethyl group and the like can be mentioned.
  • the “C6-14 aryl C1-6 alkyloxy group” of the above-mentioned group C includes a “C1-6 alkyloxy group” substituted by the above-defined “C6-14 aryl group optionally substituted by 1 to 3 substituent(s) selected from group B”, wherein the alkyl group moiety is substituted by 1 to 3 substituent(s) selected from the above-defined “group A”, and specifically, carbamoylphenylmethyloxy group, 1-carboxy-2-phenylethyloxy group, 1-hydroxymethyl-2-phenylethyloxy group, 1-carboxymethyl-2-phenylethyloxy group, 1-benzyloxycarbonyl-2-phenylethyloxy group and the like can be mentioned.
  • R c2 and R c3 may form, “together with the adjacent nitrogen atom, a nitrogen-containing heterocycle”, and the “nitrogen-containing heterocycle” contains at least one nitrogen atom among the above-mentioned “heterocyclic groups”, and a bond extends from the nitrogen atom.
  • the “nitrogen-containing heterocycle” may further contain, besides nitrogen atom, a hetero atom selected from oxygen atom and sulfur atom.
  • 1-pyrrolidinyl group, 3-hydroxypyrrolidin-1-yl group, 3-oxopyrrolidin-1-yl group and morpholino group can be mentioned.
  • the cycloalkyl moiety is preferably a cyclopentyl group or a cyclohexyl group.
  • R 1 is preferably and Z is preferably the above-defined “C1-6 alkylene” or *-(CH 2 ) m —Q—(CH 2 ) n —, more preferably, the above-defined “C1-6 alkylene”.
  • Ring D is preferably the above-defined “C3-10 carbon ring group optionally substituted by 1 to 3 substituent(s) selected from group B”, more preferably, a phenyl group optionally substituted by 1 to 3 substituent(s) selected from the above-defined “group B”, and more preferably, a phenyl group optionally substituted by 1 to 3 substituent(s) selected from a halogen atom and —OR b1 wherein R b1 is a hydrogen atom or a C1-6 alkyl group.
  • R 1 is preferably the above-defined “C1-6 alkyl group optionally substituted by 1 to 3 substituent(s) selected from group A”, more preferably the above-defined “C1-6 alkyl group”.
  • R 2 is preferably a hydrogen atom, a C6-14 aryl C1-6 alkyl group or —SO 2 R d1 , more preferably a hydrogen atom.
  • X is preferably —C(R x1 )(R x2 )—C(R x3 )(R x4 )-#, —C(R x1 )(R x2 )—C(R x3 )(R x4 )—C(R x5 )(R x6 )-#, —C(R x7 ) ⁇ C(R x8 )-#, —N ⁇ C(R x9 )-#, or —C(R x10 ) ⁇ N-#, more preferably —C(R x1 )(R x2 )—C(R x3 )(R x4 )-#, or —C(R x7 ) ⁇ C(R x8 )-#.
  • One of the more preferable embodiments is —C(R x1 )(R x2 )—C(R x3 )(R x4 )-#, and the other is —C(R x7 ) ⁇ C(R x8 )-#.
  • of ring B is preferably C ⁇ C(R y1 )—N(R y2 ), N—C(R y1 ) ⁇ N, N—C(R y1 ) ⁇ C(R y2 ), or C ⁇ N—N(R y2 ), more preferably N—C(R y1 ) ⁇ C (R y2 ).
  • formula [I] include the following formulas [I]-1, [I]-2, [I]-3 and [I]-4: wherein each symbol is as defined above.
  • R x1 to R x10 are preferably selected from
  • R x3 and R x4 form a C3-8 cycloalkyl together with the adjacent carbon atom.
  • R x1 to R x10 hydrogen atom, cyano group, methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, hydroxymethyl group, 1-hydroxyethyl group, 2-hydroxyethyl group, 1-hydroxypropyl group, 3-hydroxypropyl group, 1-hydroxy-2-methylpropyl group, methoxymethyl group, 2-methylsulfanylethyl group, 2-methylsulfonylethyl group, phenyl group, benzyl group, phenethyl group, 3-phenylpropyl group, carboxyl group, methoxycarbonyl group, formyl group, acetyl group, dimethylcarbamoyl group and the like can be mentioned, or R x3 and R x4 may form a cyclopentyl group or a cyclohexyl group, together with the adjacent carbon atom.
  • R x1 to R x10 are more preferably hydrogen atoms.
  • R y1 is preferably selected from
  • R y1 is specifically hydrogen atom, methyl group, isopropyl group, isobutyl group, tert-butyl group, cyanomethyl group, hydroxymethyl group, 1-hydroxyethyl group, 2-hydroxyethyl group, 1-hydroxy-2-methylpropyl group, 1-hydroxy-2,2-dimethylpropyl group, methoxymethyl group, isopropyloxymethyl group, isobutyloxymethyl group, 2-hydroxy-3,3-dimethylbutyl group, methylsulfanylmethyl group, isopropylsulfanylmethyl group, methylsulfonylmethyl group, isopropylsulfonylmethyl group, pivaloylmethyl group, phenoxymethyl group, benzyloxycarbonylmethyl group, phenyl group, carboxyl group, methoxycarbonyl group, carbamoyl group, methylcarbamoyl group, dimethylcarbamoyl group, diethylcarbamoyl
  • R y1 is particularly preferably a hydrogen atom.
  • R y2 is preferably selected from
  • R y2 is heterocyclic group.
  • R y2 is a heterocyclic group bonded to Y 3 via a carbon atom, wherein at least one of the ⁇ -position of the carbon atom is a hetero atom selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom.
  • the heterocyclic group is optionally substituted by 1 to 3 substituent(s) selected from group B, and specifically, 2-thiazolyl group, 4-methyl-thiazol-2-yl group, 5-methyl-thiazol-2-yl group, 5-thiazolyl group, 2-oxazolyl group, 1-methyl-imidazol-2-yl group, 3-pyrazolyl group, 1,2,4-triazol-3-yl group, 2-methyl-1,2,4-triazol-3-yl group, 5-tetrazolyl group, 3-methyl-1,2,4-thiadiazol-5-yl group, 2-pyridyl-group, 2-pyrimidinyl group, 4-pyrimidinyl group, 2-pyrazinyl group, 3-pyridazinyl group, 2-benzofuranyl group and the like can be mentioned.
  • R y2 include —CO 2 R c1 (carboxyl group, methoxycarbonyl group, isopropyloxycarbonyl group, 2,2-dimethylpropyloxycarbonyl group and cyclohexyloxycarbonyl group can be specifically mentioned), —CONR c2 R c3 (carbamoyl group, methylcarbamoyl group, ethylcarbamoyl group, propylcarbamoyl group, isopropylcarbamoyl group, butylcarbamoyl group, isobutylcarbamoyl group, dimethylcarbamoyl group, diethylcarbamoyl group, N-butyl-N-methylcarbamoyl group, 2-fluoroethylcarbamoyl group, 2-hydroxyethylcarbamoyl group, 2-methoxyethylcarbamoyl group, N-methyl
  • R c4 is more preferably an unsubstituted C1-6 alkyl group.
  • R y2 include
  • R y2 is still more preferably —NR c6 COR c7 , —NR c8 SO 2 R c9 , —NR c13 CONR c14 R c15 , —NR c16 CO 2 R c17 or —NR c18 COCOR c19 , particularly preferably —NR c6 COR c7 (R c6 is more preferably a hydrogen atom and R c7 is more preferably an unsubstituted C1-6 alkyl group).
  • the “pharmaceutically acceptable salt thereof” may be any salt as long as it forms a non-toxic salt with the compounds of the above-mentioned formulas [I], [I]-1, [I]-2, [I]-3 and [I]-4, and can be obtained by a reaction with an inorganic acid such as hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid and the like; an organic acid such as oxalic acid, malonic acid, citric acid, fumaric acid, lactic acid, malic acid, succinic acid, tartaric acid, acetic acid, trifluoroacetic acid, gluconic acid, ascorbic acid, methylsulfonic acid, benzylsulfonic acid and the like; an inorganic base such as sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, ammonium hydroxide and the like; an organic base such as methylamine, diethylamine, triethylamine, triethanolamine, ethylened
  • the present invention also encompasses prodrugs and metabolites of each compound.
  • prodrug is meant a derivative of the compound of the present invention, which has a chemically or metabolically decomposable group and which, after administration to a body, restores to the original compound to show its inherent efficacy, including a complex and a salt free of covalent bond.
  • the prodrug is utilized for, for example, improving absorption by oral administration or targeting of a target site.
  • hydroxyl-modifying group examples include methyl group, benzyl group, trimethylsilyloxymethyl group, acetyl group, propionyl group, isobutyryl group, pivaloyl group, benzoyl group, 4-methylbenzoyl group, dimethylcarbamoyl group, sulfo group and the like.
  • carboxyl-modifying group examples include ethyl group, pivaloyloxymethyl group, 1-(acetyloxy)ethyl group, 1-(ethoxycarbonyloxy)ethyl group, 1-(cyclohexyloxycarbonyloxy)ethyl group, carboxylmethyl group, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl group, phenyl group, o-tolyl group and the like.
  • amino-modifying group examples include hexylcarbamoyl group, 3-methylthio-1-(acetylamino)propylcarbonyl group, 1-sulfo-1-(3-ethoxy-4-hydroxyphenyl)methyl group, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl group and the like.
  • prodrugs of the compounds of the formulas [I], [I]-1, [I]-2, [I]-3 and [I]-4, wherein the hydroxyl group on ring B is modified by methyl group, benzyl group or trimethylsilyloxymethyl group can be mentioned.
  • the compound of the present invention can be administered to a mammal (human, mouse, rat, hamster, rabbit, cat, dog, bovine, sheep, monkey and the like) as an anti-HIV agent, an integrase inhibitor, an antiviral agent and the like.
  • the compound of the present invention When the compound of the present invention is used as a pharmaceutical preparation, it is admixed with pharmaceutically acceptable carriers, excipients, diluents, extending agents, disintegrants, stabilizers, preservatives, buffers, emulsifiers, flavoring agents, coloring agents, sweetening agents, thickeners, correctives, dissolution aids, and other additives, that are generally known per se, such as water, vegetable oil, alcohol (e.g., ethanol or benzyl alcohol etc.), polyethylene glycol, glycerol triacetate, gelatin, carbohydrate (e.g., lactose, starch etc.), magnesium stearate, talc, lanolin, petrolatum and the like, formed into tablet, pill, powder, granule, suppository, injection, eye drop, liquid, capsule, troche, aerosol, elixir, suspension, emulsion, syrup and the like by a conventional method, and administered systemically or topically
  • the dose varies depending on age, body weight, symptom, treatment effect, administration method and the like, it is generally 0.01 mg to 1 g per administration for an adult, which is given once to several times a day orally or in a dosage form of an injection such as intravenous injection and the like.
  • a compound having high pharmacological activity e.g., a compound having a strong HIV integrase-inhibitory activity, a compound having a strong anti-HIV (e.g., HIV-1 IIIB strain) activity, a compound that resists easy occurrence of drug resistant viruses, a compound effective against multiple drug resistant viruses), a compound having fine bioavailability (e.g., a compound showing high oral absorbability, a compound showing high cell membrane (e.g., Caco2) permeability, a compound stable to metabolic enzyme (e.g., S9), a compound maintained at high blood concentration for a long time (e.g., high blood concentration after 8 hours from administration), a compound showing low binding rate to a protein (e.g., human plasma protein, human serum albumin, ⁇ 1-acidic glycoprotein), a highly safe compound (e.g., a compound showing low inhibitory activity against P450(CYP)) and the like can be mentioned.
  • a protein e.g., human plasma
  • An anti-HIV agent is generally required to sustain its effect for a long time, so that can be effective not only for temporal suppression of viral growth but also prohibition of viral re-growth. This means that a prolonged administration is necessary and that a high single dose may be frequently inevitable to sustain effect for a longer period through the night. Such prolonged and high dose administration increases the risk of causing side effects.
  • one of the preferable modes of the nitrogen-containing fused ring compound of the present invention is such compound permitting high absorption by oral administration, and such compound capable of maintaining blood concentration of the administered compound for an extended period of time.
  • a compound that exhibits a strong anti-HIV activity, high absorbability by oral administration, and long-term sustention of blood concentration is desirable.
  • a compound showing less effect of addition of serum e.g., human serum, fetal bovine serum, equine serum
  • serum e.g., human serum, fetal bovine serum, equine serum
  • capable of maintaining strong integrase inhibitory activity and strong anti-HIV activity is also one of the preferable embodiments.
  • prophylaxis of AIDS is meant, for example, administration of a pharmaceutical agent to an individual who tested HIV positive but has not yet developed the disease state of AIDS, administration of a pharmaceutical agent to an individual who shows an improved disease state of AIDS after treatment but who carries HIV still to be eradicated and whose relapse of AIDS is concerned, and administration of a pharmaceutical agent out of a fear of possible infection.
  • Examples of the “other anti-HIV agents” to be used for a multiple drug combination therapy include an anti-HIV antibody, an HIV vaccine, immunostimulants such as interferon and the like, an HIV ribozyme, an HIV antisense drug, a reverse transcriptase inhibitor, a protease inhibitor, an inhibitor of bond between a bond receptor (CD4, CXCR4, CCR5 and the like) of a host cell recognized by virus and the virus, and the like.
  • an anti-HIV antibody an HIV vaccine, immunostimulants such as interferon and the like
  • an HIV ribozyme an HIV antisense drug
  • a reverse transcriptase inhibitor a reverse transcriptase inhibitor
  • a protease inhibitor an inhibitor of bond between a bond receptor (CD4, CXCR4, CCR5 and the like) of a host cell recognized by virus and the virus, and the like.
  • HIV reverse transcriptase inhibitor examples include Retrovir(R) (zidovudine), Epivir(R) (lamivudine), Zerit(R) (sanilvudine), Videx(R) (didanosine), Hivid(R) (zalcitabine), Ziagen(R) (abacavir sulfate) Viramune(R) (nevirapine), Stocrin(R) (efavirenz), Rescriptor(R) (delavirdine mesylate), Combivir(R) (zidovudine+lamivudine), Trizivir(R) (abacavir sulfate+lamivudine+zidovudine), Coactinon(R) (emivirine), Phosphonovir(R), Coviracil(R), alovudine (3′-fluoro-3′-deoxythymidine), Thiovir (thiophosphonoformic acid), Capravirin (5-[(3,5-[
  • HIV protease inhibitor examples include Crixivan(R) (indinavir sulfate ethanolate), saquinavir, Invirase(R) (saquinavir mesylate), Norvir(R) (ritonavir), Viracept(R) (nelfinavir mesylate), lopinavir, Prozei(R) (amprenavir), Kaletra(R) (ritonavir+lopinavir), mozenavir dimesylate ([4R-(4 ⁇ ,5 ⁇ ,6 ⁇ )]-1,3-bis[(3-aminophenyl)methyl]-hexahydro-5,6-dihydroxy-4,7-bis(phenylmethyl) -2H-1,3-diazepin-2-one dimethanesulfonate), tipranavir (3′-[(1R)-1-[(6R)-5,6-dihydro-4-hydroxy-2-oxo-6-phenyle
  • the HIV integrase inhibitor is exemplified by S-1360 and the like
  • the DNA polymerase inhibitor or DNA synthesis inhibitor is exemplified by Foscavir(R), ACH-126443 (L-2′,3′-didehydro-dideoxy-5-fluorocytidine), entecavir ((1S,3S,4S)-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]guanine), calanolide A ([10R-(10 ⁇ ,11 ⁇ ,12 ⁇ )]-11,12-dihydro-12-hydroxy-6,6,10,11-tetramethyl-4-propyl-2H,6H,10H-benzo[1,2-b:3,4-b′:5,6-b′′]tripyran-2-one), calanolide B, NSC-674447 (1,1′-azobisformamide), Iscador (viscum album extract) and the like
  • the HIV antisense drug is exemplified by HG
  • Neurotropin(R), Lidakol(R), Ancer 20(R), Ampligen(R), Anticort(R), Inactivin(R) and the like PRO-2000, Rev M10 gene, HIV specific cytotoxic T cell (CTL immunotherapy, ACTG protocol 080 therapy, CD4- ⁇ gene therapy), SCA binding protein, RBC-CD4 complex and the like are exemplified.
  • anti-HIV agents As the “other anti-HIV agents” to be used for a multiple drug combination therapy with the compound of the present invention, preferred are a reverse transcriptase inhibitor and a protease inhibitor. Two or three, or even a greater number of pharmaceutical agents can be used in combination, wherein a combination of pharmaceutical agents having different action mechanisms is one of the preferable embodiments. In addition, selection of pharmaceutical agents free of side effect duplication is preferable.
  • combination of pharmaceutical agents include a combination of a group consisting of efavirenz, indinavir, nelfinavir, ritonavir+indinavir, ritonavir+lopinavir and ritonavir+saquinavir, and a group consisting of didanosine+lamivudine, zidovudine+didanosine, stavudine+didanosine, zidovudine+lamivudine and stavudine+lamivudine (Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Aug. 13, 2001). Particularly preferred is Invirase(R) (saquinavir mesylate).
  • the work-up treatment in each step can be applied by a typical method, wherein isolation and purification is performed by selecting or combining conventional methods as necessary, such as crystallization, recrystallization, distillation, partitioning, column chromatography, thin layer chromatography, preparative HPLC and the like.
  • Me means methyl group
  • Et means ethyl group
  • Bn means benzyl group
  • n-Bu (or Bu) means butyl group
  • t-Bu means tert-butyl group
  • Ac means acetyl group
  • Boc means tert-butoxycarbonyl group
  • MOM means methoxymethyl group
  • Ms means methanesulfonyl group.
  • L 1 is a leaving group such as a chlorine atom, a bromine atom, a methanesulfonyloxy group, a trifluoromethanesulfonyloxy group, a toluenesulfonyloxy group and the like
  • W 1 is a protecting group such as an acetyl group, a benzoyl group, a benzyl group, a methoxyethoxymethyl group, a tert-butyldimethylsilyl group and the like, or a hydrogen atom, and other symbols are as defined above.
  • Compound [I] can be synthesized by reacting compound [1] in an organic solvent such as tetrahydrofuran, dioxane, dimethylformamide, dimethylacetamide, N-methylpyrrolidone, 1,3-dimethyl-2-imidazolidinone, tert-butanol, isopropanol and the like, in the presence of a base such as sodium hydride, lithium diisopropylamide, lithium bis(trimethylsilyl)amide, potassium tert-butoxide, triethylamine, diisopropylethylamine and the like at room temperature to cooling to give Compound [I].
  • organic solvent such as tetrahydrofuran, dioxane, dimethylformamide, dimethylacetamide, N-methylpyrrolidone, 1,3-dimethyl-2-imidazolidinone, tert-butanol, isopropanol and the like
  • a base such as sodium hydride, lithium
  • a compound represented by the formula [I-1] can be synthesized by subjecting compound [2] to a ring closure reaction under acidic conditions in a solvent or without solvent at room temperature to under heating.
  • inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, polyphosphoric acid and the like
  • organic acids such as acetic acid, trifluoroacetic acid, camphorsulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, trifluoromethanesulfonic acid and the like
  • acidic salts such as pyridinium p-toluenesulfonate and the like, and the like
  • solvent ether solvents such as tetrahydrofuran, dioxane, diethyl ether and the like
  • benzene solvents such as benzene, toluene, chlorobenzene, dichlorobenzene and the like
  • alcohol solvents such as ethanol, isopropanol, tert-butanol and the like
  • halogenated hydrocarbon solvents such as methylene chloride, chloroform, dichlor
  • a combination of an organic acid and a benzene solvent often produce good results.
  • preferable options include, for example, a reaction under the conditions of using an acid such as phosphoric acid, polyphosphoric acid, sulfuric acid and the like without using a solvent, and the conditions of using acetic acid or trifluoroacetic acid as a solvent and adding aqueous hydrochloric acid thereto.
  • Production Method 2 wherein W 2 is an alkyl group such as methyl group, ethyl group and the like, or a hydrogen atom, and other symbols are as defined above.
  • Compound [I] can be synthesized by subjecting compound [3] to ring closure reaction under acidic or basic conditions at room temperature to under heating.
  • a ring closure reaction can be achieved using a condensation agent such as dicyclohexylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, carbonyldiimidazole and the like and conducting a reaction in the presence or absence of a condensation additive such as 1-hydroxybenzotriazole, N-hydroxysuccinimide and the like in an ether solvent such as tetrahydrofuran, dioxane, diethyl ether and the like, a benzene solvent such as benzene, toluene and the like, a hydrocarbon solvent such as cyclohexane and the like, an amide solvent such as dimethylformamide, dimethylacetamide, 1,3-dimethylimidazolidinone and the like, a ketone solvent such as acetone, 2-butanone and the like or a halogenated hydrocarbon solvent such as m
  • a condensation agent such as dicyclohe
  • a ring closure reaction can be achieved by conducting a reaction in the presence of an acid catalyst such as camphorsulfonic acid, p-toluenesulfonic acid and the like or a base catalyst such as dimethylaminopyridine and the like in a solvent such as benzene, toluene and the like at room temperature to under heating, particularly preferably under heating.
  • an acid catalyst such as camphorsulfonic acid, p-toluenesulfonic acid and the like or a base catalyst such as dimethylaminopyridine and the like
  • a solvent such as benzene, toluene and the like
  • Compound [I-2] can be synthesized by reacting compound [4] in an organic solvent such as tetrahydrofuran, dioxane, dimethylformamide, dimethylacetamide, N-methylpyrrolidone, 1,3-dimethyl-2-imidazolidinone, tert-butanol, isopropanol, ethanol and the like, or a mixed solvent of these with water, in the presence or absence of an organic base such as triethylamine, diisopropylethylamine and the like or a carbonate base such as sodium carbonate, potassium carbonate, sodium hydrogen carbonate and the like at room temperature to under heating.
  • an organic base such as triethylamine, diisopropylethylamine and the like or a carbonate base such as sodium carbonate, potassium carbonate, sodium hydrogen carbonate and the like at room temperature to under heating.
  • Compound [I-2] can be synthesized by subjecting compound [5] to the same reaction operation as in Production method 1-1.
  • Production Method 3-3 wherein —X 3 —L 3 is —CH(R x7 )—C(R x8 )(OMe) 2 or —C(R x1 )(R x2 )—CH(R x7 )—C(R x8 )(OMe) 2 wherein each symbol is as defined above, when —X 3 —L 3 is —CH(R x7 )—C(R x8 )(OMe) 2 , —X 2 — is —C(R x7 ) ⁇ C(R x8 )-#, when —X 3 —L 3 is —C(R x1 )(R x2 )—CH(R x7 )—C(R x8 )(OMe) 2 , —X 2 — is —C(R x1
  • Compound [I-2] can be synthesized by subjecting compound [6] to the same reaction operation as in production method 1-2.
  • Production Method 3-4 wherein —X 4 —L 4 is —CH(R x7 )—C( ⁇ O)(R x8 ) or —C(R x1 )(R x2 )—CH(R x7 )—C( ⁇ O)(R x8 ) wherein each symbol is as defined above, when —X 4 —L 4 is —CH(R x7 )—C( ⁇ O)(R x8 ), —X 2 — is —C(R x7 ) ⁇ C(R x8 )-#, when —X 4 —L 4 is —C(R x1 )(R x2 )—CH(R x7 )—C( ⁇ O)(R x8 ), —X 2 — is —C(R x1 )(R x2 )
  • Compound [I-3] can be obtained by subjecting compound [7] to a ring closure reaction in the same manner as in Production method 3-3. wherein each symbol is as defined above.
  • a method comprising converting a carboxyl group to an acid halide, followed by condensation is highly versatile, and often leads to good results.
  • a starting compound is reacted with thionyl chloride, oxalyl chloride and the like in a halogenated hydrocarbon solvent such as methylene chloride, chloroform and the like or a benzene solvent such as benzene, toluene and the like in the presence or absence of a catalytic amount of dimethylformamide, thereafter reacted in the presence of a base to complete the condensation reaction.
  • a base to be used include potassium carbonate, sodium carbonate, sodium hydrogen carbonate, triethylamine, pyridine and the like, and good results are often obtained when an organic base such as triethylamine, pyridine and the like is used.
  • Compound [8], compound [10] and compound [13] can be prepared by a method described in JP-A-2-502281 (WO88/06588), WO03/016275, J. Med. Chem., 42, 4814-4823, 1999 and the like, or a method analogous thereto.
  • Compound [9], compound [11], compound [12] and compound [14] can be prepared as a secondary amine by a conventional method.
  • L 5 is a leaving group such as chlorine atom, bromine atom, methanesulfonyloxy group, trifluoromethanesulfonyloxy group, toluenesulfonyloxy group and the like, and other symbols are as defined above.
  • Compound [17] can be obtained by reacting compound [15] or compound [18] as illustrated above in the same manner as in Production method 3.
  • the methods usually employed for general organic reactions often produce good results, wherein they may be protected beforehand and deprotected after the reaction, or condensation reaction is conducted in the form of a stable precursor and thereafter converted to a desired form and the like.
  • L 5 may be R 1 —NH—.
  • L 5 —X— may be C(R x7 )(OMe) 2 —CH(R x8 )— or C(R x7 )(OMe) 2 —CH(R x8 )—C(R x1 )(R x2 )— wherein each symbol is as defined above. wherein each symbol is as defined above.
  • Compound [15] and compound [18] can be obtained by performing a condensation amidation reaction as illustrated above in the same manner as in Production method 2.
  • Compound [I]-1 wherein, in the formula [I], is N—C(R y1 ) ⁇ C(R y2 ), can be synthesized by the aforementioned production methods (except Production method 3-4). wherein L 6 is L 1 or L 2 , L 7 is L 1 or L 3 , and other symbols are as defined above.
  • the production method of each step may be as described for each Production method No. indicated in the scheme.
  • Compound [10′] can be obtained by reacting compound [8′] with NH 3 .
  • Compound [8′-2] can be obtained by reacting compound [8′-1] with a brominating reagent such as bromine, phenyltrimethylammonium tribromide and the like.
  • chloroform has high versatility, but acetic acid, toluene, chlorobenzene and the like may be also used.
  • an alcohol solvent such as methanol, ethanol and the like may be used in combination with these solvents.
  • R y2 is C1-7 alkyl group, C3-8 cycloalkyl C1-6 alkyl group, C6-14 aryl C1-6 alkyl group, C1-6 alkyloxy group, C6-14 aryl C1-6 alkyloxy group, C6-14 aryl group, heterocyclic group, cyano group, —CO 2 R c1 , —CONR c2 R c3 , —SO 2 NR c2 R c3 , C6-14 arylcarbonyl group, —NR c4 R c5 , —NR c6 COR c7 , —NR c8 SO 2 R c9 , —NR c13 CONR c14 R c15 , —NR c16 CO 2 R c17 or —NR c18 COCOR c19 , wherein each symbol is as defined above.
  • Synthesis is performed according to a method described in
  • R y2 is C6-14 aryl group or heterocyclic group.
  • the corresponding compound [8′-3] can be obtained by heating compound [8′-2] and R y2 —SnBu 3 in dioxane in the presence of a catalytic amount of tetrakis(triphenylphosphine)palladium(0).
  • R y2 is C1-7 alkyl group, C3-8 cycloalkyl C1-6 alkyl group or C6-14 aryl C1-6 alkyl group.
  • a desired compound [8′-3] can be obtained by, for example, reacting compound [8′-2] with R y2 —SnBu 3 in the same manner as above.
  • R y2 is R y2 ′—CX 5 H—CY 5 H—
  • X 5 and Y 5 are each a lower alkyl group such as methyl group, ethyl group and the like and R y2 ′ is a group such as a C1-7 alkyl group, a C3-8 cycloalkyl C1-6 alkyl group and a C6-14 aryl C1-6 alkyl group, wherein the alkyl moiety is free of CX 5 H—CY 5 H moiety
  • fine results are often obtained by using R y2 ′—CX 5 ⁇ CY 5 —SnBu 3 to give compound [8′-3] wherein R y2 is R y2 ′—CX 5 ⁇ CY 5 —, and subjecting this compound to a catalytic reduction to give compound [8′-3] wherein R y2 is R y2 ′—CX 5 H—CY 5 H—.
  • R y2 is C1-6 alkyloxy group or C6-14 aryl C1-6 alkyloxy group.
  • a desired compound [8′-3] can be obtained by, for example, reacting compound [8′-2] with R y2 ′ONa (wherein R y2 ′ is a C1-6 alkyl group or C6-14 aryl C1-6 alkyl group) in toluene in the presence of bis(dibenzylideneacetone)palladium(0) or 1,1′-bis(diphenylphosphino)ferrocene.
  • the corresponding compound [8′-3] can be obtained by, for example, heating compound [8′-2] and zinc cyanide in the presence of a catalytic amount of tetrakis(triphenylphosphine)palladium(0) in dimethylformamide.
  • a compound [8′-3] wherein R y2 is —CO 2 R c1 can be obtained by, for example, heating compound [8′-2] under a carbon monoxide atmosphere in dimethyl sulfoxide in the presence of R c1 OH, triethylamine, palladium(II) acetate and 1,3-bis(diphenylphosphino)propane.
  • a compound [8′-3] wherein R y2 is —CO 2 H can be obtained by using methanol for R c1 OH to give compound [8′-3], wherein R y2 is —CO 2 CH 3 , and subjecting this compound to hydrolysis by a conventional method using aqueous sodium hydroxide solution/tetrahydrofuran and the like.
  • Compound [8′-3] wherein R y2 is —CONR c2 R c3 can be obtained by condensation of this compound with NHR c2 R c3 .
  • the condensation reaction can be carried out according to the aforementioned production method 2 and production method 4.
  • a desired compound [8′-3] can be obtained by, for example, heating compound [8′-2] and HNR c4 R c5 in the presence of cesium carbonate and a catalytic amount of palladium(II) acetate and 2,2′-bis(di-tert-butylphosphino)-1,1′-binaphthyl in benzene.
  • R y2 is —NRC c6 COR c7 , —NR c8 SO 2 R c9 , —NR c13 CONR c14 R c15 , —NR c16 CO 2 R c17 or —NR c18 COCOR c19 .
  • Compound [8′-3] wherein R y2 is —NR c6 COR c7 can be obtained by, for example, heating compound [8′-2] and HNR c6 COR c7 in toluene in the presence of sodium tert-butoxide and a catalytic amount of palladium(II) acetate or 1,1′-bis(diphenylphosphino)ferrocene.
  • the corresponding compound [8′-3] can be synthesized by reacting the obtained compound [8′-5] with the corresponding carboxylic acid (e.g., R c7 CO 2 H), carboxylic acid anhydride (e.g., R c7 CO 2 COR c7 ) or acid chloride (e.g., R c7 COCl), chlorocarbonic acid ester (R c17 OCOCl), isocyanate (R c14 —NCO), chlorocarbonic acid amide (R c14 R c15 NCOCl), sulfonyl chloride (R c9 SO 2 Cl) and the like, as described in the above-mentioned Production method 2 and Production method 4.
  • carboxylic acid e.g., R c7 CO 2 H
  • carboxylic acid anhydride e.g., R c7 CO 2 COR c7
  • acid chloride e.g., R c7 COCl
  • chlorocarbonic acid ester R
  • R c6 , R c8 , R c13 , R c16 , or R c18 may be introduced into —NH 2 prior to the above-mentioned reactions or after the reactions by a conventional method.
  • Compound [8′-4] can be obtained by reacting compound [8′-1] with nitric acid, fuming nitric acid, nitronium tetrafluoroborate and the like.
  • acetic acid As the solvent, acetic acid, chloroform and the like are generally used and various conditions known as nitration conditions of aromatic ring may be used.
  • Compound [8′-5] can be obtained by subjecting [8′-4] to catalytic reduction, reduction with a metal powder such as iron, zinc and the like, or reduction with a metal ion such as tin chloride and the like.
  • acetic acid As a solvent for reduction with a metal powder, acetic acid, hydrochloric acid-alcohol, hydrochloric acid-tetrahydrofuran and the like are generally used and for reduction using tin chloride, methanol or ethanol is generally used.
  • introduction of Br and conversion to R y2 are not limited by compound [8] and can be performed at a desired or suitable timing in the whole steps in the already described Production methods, wherein introduction of Br and conversion to R y2 may be conducted in different steps. Particularly, introduction of Br sometimes provide fine results when done in compound [5], [6], [10], [17], [18], [10] or [I-1].
  • E is a functional group derived from an electrophile corresponding to R y2 such as —COR c4 , —COOH, —SR c10 and the like, and each symbol is as defined above.
  • electrophile examples include esters, aldehydes, ketones, disulfides, carbon dioxide and the like.
  • lithium diisopropylamide, potassium hexamethyldisilamide, n-butyllithium and the like can be mentioned, and as a solvent, tetrahydrofuran, diethyl ether, dimethoxyethane and the like can be mentioned.
  • tetrahydrofuran, diethyl ether, dimethoxyethane and the like can be mentioned.
  • the reaction temperature when a reaction is carried out at room temperature to under cooling, fine results are often obtained. In this way, the introduced functional group can be also converted to a desired and suitable R y2 by various known reactions.
  • Compound [15′-2] wherein R y2 is —CH(OH)R c4 can be obtained by adding R c4 —CHO as an electrophile to compound [15′-1] treated with lithium diisopropylamide at ⁇ 78° C. in tetrahydrofuran.
  • R y2 is —COOH, —SR c10 , —SOR c11 or —SO 2 R c12 .
  • compound [15′-2] wherein R y2 is —COOH or —SR c10 can be obtained.
  • Compound [15′-2] wherein R y2 is —SR c10 is treated with a peracid such as m-chloroperbenzoic acid and the like in chloroform, whereby compound [15′-2] wherein R y2 is —SOR c11 or —SO 2 R c12 can be obtained.
  • the introduction of E by electrophile and conversion to R y2 are not limited by compound [15] and can be performed at a desired or suitable timing in the whole steps in the already described Production methods, wherein introduction of E and conversion to R y2 may be conducted in different steps.
  • Compound [I-5] can be obtained by converting compound [10′] to compound [19] and sequentially condensing the compound with a compound represented by R x9 —CH(OMe) 2 .
  • R 1 —NHNH—W (W is amino-protecting group) is used instead of R 1 —NH 2 , and a method according to the method described in Production method 6 is performed.
  • a condensation reaction of compound [19] to compound [I-5] is carried out in the presence of an acid catalyst such as hydrochloric acid, p-toluenesulfonic acid, pyridinium p-toluenesulfonate and the like in a benzene solvent such as benzene, toluene, chlorobenzene and the like or an alcohol solvent such as methanol, ethanol and the like at room temperature to under heating. wherein each symbol is as defined above.
  • an acid catalyst such as hydrochloric acid, p-toluenesulfonic acid, pyridinium p-toluenesulfonate and the like
  • a benzene solvent such as benzene, toluene, chlorobenzene and the like or an alcohol solvent such as methanol, ethanol and the like at room temperature to under heating. wherein each symbol is as defined above.
  • Compound [I-6] can be obtained by converting compound [8′] to compound [20] and sequentially condensing with a compound represented by R x10 —CH(OMe) 2 .
  • W—NH—NH 2 (W is amino-protecting group) is used instead of L 5 —X—NH 2 , and a method according to the method described in Production method 5 is performed.
  • a condensation reaction of compound [20] to compound [I-6] is carried out under acidic conditions in the same manner as in Production method 8-1. wherein each symbol is as defined above.
  • Compound [I]-2 is a part of the compound represented by the formula [I] and produced according to the aforementioned method, wherein preferable results are often obtained when the production follows this production method.
  • compound [22] is synthesized by reacting compound [21] prepared according to the a method described in a reference (Breslow, D. S. et al., J. Am. Chem. Soc., 1946, 68, 1232) or a method analogous thereto with R y1—C(NH 2 ) ⁇ NH under acidic conditions or basic conditions.
  • acid to be used hydrochloric acid, p-toluenesulfonic acid and the like can be mentioned, and the acid is generally applied to the reaction in the form of an amidine salt. Where necessary, the acid may be further added.
  • sodium methoxide, potassium carbonate and the like can be mentioned, and as the solvent, methanol, ethanol, dioxane, tetrahydrofuran and the like can be mentioned.
  • This reaction can be carried out in such a solvent that does not particularly inhibit the reaction under comparatively wide pH conditions.
  • conditions under which the reaction is carried out in methanol using sodium methoxide as a base under heating can be mentioned.
  • the subsequent production step to produce compound [I]-2 from compound [22] via compound [23] is performed according to the aforementioned Production method 4 and Production method 3. Prior to this conversion, it is necessary to hydrolyze compound [22] into carboxylic acid in a solvent such as alcohol, tetrahydrofuran and the like using sodium hydroxide and the like. wherein each symbol is as defined above.
  • compound [24] derived from amino acid is reacted with methyl orthoformate in methanol or without solvent in the presence of an acid catalyst such as hydrochloric acid, p-toluenesulfonic acid, pyridinium p-toluenesulfonate and the like, and thereafter deprotected, whereby compound [25] can be obtained.
  • an acid catalyst such as hydrochloric acid, p-toluenesulfonic acid, pyridinium p-toluenesulfonate and the like
  • Compound [26] can be obtained by reacting compound [25] with methyl chloroglyoxylate in the presence of a base such as pyridine, triethylamine and the like in a solvent such as chloroform, toluene, tetrahydrofuran and the like or without solvent. Fine results are often obtained when this reaction is carried out under cooling.
  • a base such as pyridine, triethylamine and the like
  • a solvent such as chloroform, toluene, tetrahydrofuran and the like or without solvent. Fine results are often obtained when this reaction is carried out under cooling.
  • Compound [27] can be obtained by reacting compound [26] with W 2 —OAc.
  • W 2 —OAc fine results are often obtained when W 2 —OAc is treated with a base such as lithium diisopropylamide, lithium hexamethyldisilamide and the like in a solvent such as tetrahydrofuran and the like to give an enolate, which is then reacted with compound [26].
  • a base such as lithium diisopropylamide, lithium hexamethyldisilamide and the like
  • solvent such as tetrahydrofuran and the like
  • Compound [28] can be obtained by hydrolyzing compound [27] under acidic conditions.
  • acid to be used 4N (or below) hydrochloric acid is preferable, and the reaction is carried out in tetrahydrofuran or dioxane.
  • Compound [29] can be obtained by treating compound [28] with a base.
  • a base such as potassium carbonate, sodium carbonate and the like, a metal amide such as lithium diisopropylamide, potassium hexamethyldisilamide and the like, and an organic base such as triethylamine, ethyldiisopropylamine, pyridine and the like can be mentioned, and preferable results are often obtained when triethylamine, ethyldiisopropylamine and the like are used.
  • solvent for example, chloroform, tetrahydrofuran, dioxane, methanol, ethanol, toluene and the like can be mentioned, which are obviously subject to limitation depending on the kind of a base to be used.
  • a step to produce compound [I]-3 from compound [29] via compound [30] can be performed according to the aforementioned Production method 5 and Production method 1-1 or 1-2. wherein each symbol is as defined above.
  • Compound [32] can be synthesized by reacting compound [31] prepared by the method described in a reference (Micovic, I.V. et al., J. Chem. Soc., Perkin Trans. 1(1996) 16, 2041) or a method analogous thereto with a compound H 2 N—NH—R y2 in a solvent such as methanol, ethanol, tetrahydrofuran, dioxane, toluene and the like at room temperature to under heating.
  • a solvent such as methanol, ethanol, tetrahydrofuran, dioxane, toluene and the like
  • Compound [I]-4 can be obtained by reacting compound [32] with oxalyl chloride in the presence of an organic base such as triethylamine, ethyldiisopropylamine, pyridine and the like in a solvent such as chloroform, tetrahydrofuran, dioxane, toluene and the like. While the reaction temperature is subject to no limitation, preferable results are often obtained when the reaction is carried out under cooling to room temperature.
  • an organic base such as triethylamine, ethyldiisopropylamine, pyridine and the like
  • a solvent such as chloroform, tetrahydrofuran, dioxane, toluene and the like.
  • step 1 N-(3,4-Dichlorobenzyl)-3-benzyloxy-4-oxo-4H-pyran-2-carboxamide (60 mg) obtained in the same manner as in Example 1, step 1 was dissolved in tetrahydrofuran (0.5 ml), ethanol (0.5 ml) and water (0.1 ml), and 3-amino-1-propanol (0.0226 ml) and sodium carbonate (8 mg) were successively added. The mixture was stirred at room temperature for 7 hr.
  • N-(3,4-Dichlorobenzyl)-3-benzyloxy-1-(3-hydroxypropyl)-4-oxo-1,4-dihydropyridine-2-carboxamide (30 mg) obtained in the previous step was dissolved in tetrahydrofuran (1.5 ml) and the mixture was cooled to 0° C. under an argon atmosphere.
  • Diisopropylethylamine (0.034 ml) and methanesulfonyl chloride (0.0065 ml) were successively added dropwise at the same temperature and the mixture was stirred at room temperature for 2 hr.
  • N-(3,4-Dichlorobenzyl)-3-benzyloxy-4-oxo-4H-pyran-2-carboxamide (50 mg) obtained in the same manner as in Example 1, Step 1 was dissolved in tetrahydrofuran (0.5 ml), ethanol (0.5 ml) and water (0.1 ml). DL-1-Amino-2-propanol (0.0191 ml) and sodium carbonate (7 mg) were successively added, and the mixture was stirred overnight at room temperature.
  • the crude crystals (1.0 g) of tert-butyl [1-(3,4-dichlorobenzylcarbamoyl)-1-methylethyl]carbamate obtained in the previous step was dissolved in tetrahydrofuran (5 ml) and cooled to 0° C. under an argon atmosphere.
  • a borane—tetrahydrofuran complex (1.0 M/tetrahydrofuran solution)(15 ml) was added dropwise at the same temperature, removed from an ice-bath and stirred at room temperature for 2 hr.
  • a borane—tetrahydrofuran complex (1.0 M/tetrahydrofuran solution)(5 ml) was added every 30 minutes twice in total.
  • tert-Butyl N-(2-aminoethyl) carbamate (1.51 g) was dissolved in chloroform (20 ml) and 3,4-dichlorobenzaldehyde (1.65 g), acetic acid (0.54 ml) and sodium triacetoxyborohydride (2.6 g) were added at room temperature. The mixture was stirred overnight. Saturated aqueous sodium hydrogen carbonate solution was added to the obtained reaction mixture and the mixture was stirred and extracted three times with chloroform. The combined organic layer was washed with saturated brine and dried over sodium sulfate.
  • the solvent was evaporated and the obtained solid was washed with ethyl acetate/hexane.
  • N-(3,4-Dichlorobenzyl)-3-benzyloxy-1-(2-hydroxypropyl)-4-oxo-1,4-dihydropyridine-2-carboxamide (0.250 g) obtained in the previous step was dissolved in chloroform (10 ml), Dess-Martin reagent (0.5 g) was added, and the mixture was stirred overnight at room temperature. The obtained reaction mixture was washed with saturated aqueous sodium hydrogen carbonate solution and dried over magnesium sulfate.
  • Lithium aluminum hydride (1.31 g) was suspended in tetrahydrofuran (30 ml) and 3-(2,6-dichlorophenyl)acrylic acid (4.62 g) was added dropwise under ice-cooling over about 20 min. During the dropwise addition, tetrahydrofuran (20 ml) was added. After stirring at 0° C. for 3.5 hr, the mixture was stirred at room temperature for 18 hr. 4N Aqueous potassium hydroxide solution was added to the reaction mixture and a solid component was filtered off. The filtrate was concentrated under reduced pressure, and to the residue was added 1N aqueous hydrochloric acid solution.
  • Trifluoroacetic acid (1 ml) was added to 9-benzyloxy-2-[3-(2,6-dichlorophenyl)propyl]-2H-pyrido[1,2-a]pyrazine-1,8-dione (120 mg) obtained in the previous step and the mixture was left standing at room temperature for 1 hr. The solvent was evaporated, toluene was added, and the mixture was concentrated, which operations were performed twice. The obtained crystals were washed with diisopropyl ether to give 2-[3-(2,6-dichlorophenyl)propyl]-9-hydroxy-2H-pyrido[1,2-a]pyrazine-1,8-dione (92 mg).
  • Example 13-92 In the same manner as in Example 1-12 or by a similar method or by a conventional method, the compounds of Example 13-92 to be shown in the Tables below were obtained.
  • This solid was suspended in tetrahydrofuran (0.4 ml)-methanol (1 ml)-chloroform (1 ml) and 2N aqueous sodium hydroxide solution (0.043 ml) was added. The mixture was stirred at room temperature for 30 min. The reaction mixture was concentrated, 1N aqueous hydrochloric acid (6 ml) was added, and the mixture was extracted three times with chloroform (8 ml each).
  • Trifluoroacetic acid was added to the obtained residue and the mixture was stirred at 70° C. for 5.5 hr. Trifluoroacetic acid was evaporated, toluene was added and the mixture was concentrated, which operations were performed twice.
  • Methyl 9-benzyloxy-2-(3-chlorobenzyl)-1,8-dioxo-1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine-7-carboxylate (420 mg) was dissolved in tetrahydrofuran (8 ml)-water (2 ml), and 4N aqueous lithium hydroxide solution (0.58 ml) was added with stirring. After stirring at 70° C. for 1 hr, the mixture was concentrated. Water (5 ml) and then 5% aqueous potassium hydrogen sulfate solution (15 ml) were added with stirring.
  • Triethylamine (0.61 ml) and diphenylphosphoryl azide (0.47 ml) were added again and 2 hr later, and 3 hr later, triethylamine (1.22 ml, 0.61 ml) and diphenylphosphoryl azide (0.94 ml, 0.47 ml) were respectively added, and stirring was continued.
  • 9-fluorenylmethanol (7.7 g) and toluene (10 ml) were added, and the mixture was stirred under reflux with heating. After 20 min, triethylamine (2.5 ml) was added, and stirring was continued with heating for 1.5 hr.
  • Example 349 By subjecting 7-amino-9-benzyloxy-2-(3-chloro-4-fluorobenzyl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,8-dione (29 mg) obtained in Example 349, Step 2 to a reaction operation similar to that in Example 349, Steps 3 and 4 except that methanesulfonyl chloride was used instead of isobutyryl chloride, N-[2-(3-chloro-4-fluorobenzyl)-9-hydroxy-1,8-dioxo-1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methanesulfonamide (4.7 mg) was-obtained.
  • the precipitated solid was collected by filtration.
  • the obtained solid was dissolved in dimethylformamide (40 ml) and potassium carbonate (4.59 g) and benzyl bromide (3.62 ml) were added.
  • the mixture was stirred at 80° C. for 40 min.
  • the solvent was evaporated and 1N aqueous hydrochloric acid was added to the obtained residue.
  • the mixture was extracted twice with ethyl acetate.
  • the eluate was concentrated and the precipitated crystals were collected by filtration to give methyl 3-benzyloxy-5-bromo-4-oxo-4H-pyran-2-carboxylate (4.69 g).
  • Acetic acid (1.04 ml), water and ethyl acetate were successively added to the reaction mixture and the mixture was heated to room temperature and partitioned. The aqueous layer was extracted with ethyl acetate, and the combined organic layer was washed with saturated brine, dried over sodium sulfate, and concentrated under reduced pressure. Dioxane (50 ml) and 2N aqueous hydrochloric acid solution (5 ml) were added to the residue and the mixture was stirred at room temperature for 1 hr. The solvent was evaporated and subsequently, toluene was added and concentrated again.
  • reaction mixture was washed with 2N aqueous hydrochloric acid, saturated aqueous sodium hydrogen carbonate solution and saturated brine, and dried over magnesium sulfate.
  • a solution of this oil (25.6 g) in toluene (50 ml) was added dropwise to a suspension of potassium carbonate (50 g) and 18-crown-6 (1.9 g) in toluene (250 ml) with heating under reflux and the mixture was stirred at the same temperature for 12 hr.
  • reaction mixture After cooling to room temperature, the reaction mixture was poured into iced water, 6N aqueous hydrochloric acid was added to adjust the pH of the reaction mixture to not more than 1 and the mixture was extracted three times with chloroform. The chloroform layer was dried, concentrated and 10% aqueous oxalic acid solution (200 ml) was added to the obtained residue. The mixture was heated under reflux for 3 hr. The reaction mixture was cooled, extracted three times with chloroform, and dried over magnesium sulfate.
  • a free compound, a sodium salt, a potassium salt and a benzenesulfonic acid salt were obtained from the compound of Example 251 by conventional methods.
  • Examples 93-437 other than the above-mentioned compounds were obtained by methods similar or analogous to those of Examples 1-12, 118, 125, 161, 165, 94, 96, 104, 187, 191, 189, 390, 244, 251, 223, 154, 249, 219, 362, 205, 242, 382, 283, 302, 349, 353, 222, 316, 291, 106, 123, 438 and 439 or conventional methods.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US10/958,225 2003-08-13 2004-10-05 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor Abandoned US20050054645A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/255,605 US7211572B2 (en) 2003-08-13 2005-10-13 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
US11/783,270 US20080161311A1 (en) 2003-08-13 2007-04-06 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2003-293117 2003-08-13
JP2003293117 2003-08-13
JP2004-134896 2004-04-28
JP2004134896 2004-04-28
PCT/JP2004/011869 WO2005016927A1 (ja) 2003-08-13 2004-08-12 含窒素縮合環化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/011869 Continuation WO2005016927A1 (ja) 2003-08-13 2004-08-12 含窒素縮合環化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/255,605 Continuation US7211572B2 (en) 2003-08-13 2005-10-13 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor

Publications (1)

Publication Number Publication Date
US20050054645A1 true US20050054645A1 (en) 2005-03-10

Family

ID=34197143

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/958,225 Abandoned US20050054645A1 (en) 2003-08-13 2004-10-05 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
US11/255,605 Expired - Lifetime US7211572B2 (en) 2003-08-13 2005-10-13 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
US11/783,270 Abandoned US20080161311A1 (en) 2003-08-13 2007-04-06 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/255,605 Expired - Lifetime US7211572B2 (en) 2003-08-13 2005-10-13 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
US11/783,270 Abandoned US20080161311A1 (en) 2003-08-13 2007-04-06 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor

Country Status (15)

Country Link
US (3) US20050054645A1 (es)
EP (2) EP2042502A1 (es)
JP (1) JP3814631B2 (es)
AR (1) AR045367A1 (es)
AT (1) ATE411315T1 (es)
CA (1) CA2577239A1 (es)
CL (1) CL2004002061A1 (es)
DE (1) DE602004017108D1 (es)
DK (1) DK1544199T3 (es)
ES (1) ES2315700T3 (es)
PE (1) PE20050361A1 (es)
PT (1) PT1544199E (es)
SI (1) SI1544199T1 (es)
TW (1) TW200510425A (es)
WO (1) WO2005016927A1 (es)

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261322A1 (en) * 2004-05-18 2005-11-24 Naidu B N HIV integrase inhibitors
US20050288326A1 (en) * 2004-05-21 2005-12-29 Yuji Matsuzaki Combination therapy
US20060084665A1 (en) * 2004-09-21 2006-04-20 Motohide Satoh Quinolizinone compound and use thereof as HIV integrase inhibitor
WO2006116764A1 (en) * 2005-04-28 2006-11-02 Smithkline Beecham Corporation Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
US20070161639A1 (en) * 2004-03-09 2007-07-12 Philip Jones Hiv integrase inhibitors
US20070179196A1 (en) * 2004-03-09 2007-08-02 Wei Han Hiv integrase inhibitors
US20070249687A1 (en) * 2004-09-15 2007-10-25 Hiroshi Yoshida Carbamoylpyridone Derivatives Having Inhibitory Activity Against Hiv Integrase
US20080161271A1 (en) * 2005-02-21 2008-07-03 Hiroshi Yoshida Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
US20090018162A1 (en) * 2006-02-01 2009-01-15 Yuji Matsuzaki Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection
US20090253681A1 (en) * 2005-03-31 2009-10-08 Vincenzo Summa HIV Integrase Inhibitors
US20090306054A1 (en) * 2006-05-16 2009-12-10 Gilead Sciences ,Inc. Integrase inhibitors
WO2010011818A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
US20110183940A1 (en) * 2008-07-25 2011-07-28 Brian Alvin Johns Chemical compounds
AU2006244424B2 (en) * 2005-05-10 2011-09-22 Merck Sharp & Dohme Corp. HIV integrase inhibitors
JP2012511573A (ja) * 2008-12-11 2012-05-24 塩野義製薬株式会社 カルバモイルピリドンｈｉｖインテグラーゼ阻害剤及びそれらの中間体の合成
US8552187B2 (en) 2008-12-11 2013-10-08 Shionogi & Co., Ltd. Processes and intermediates for carbamoylpyridone HIV integrase inhibitors
EP2412709A4 (en) * 2009-03-26 2013-11-27 Shionogi & Co PROCESS FOR THE PREPARATION OF PYRONO AND PYRIDONE DERIVATIVES
WO2014099586A1 (en) * 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
WO2014172188A2 (en) 2013-04-16 2014-10-23 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
US8884010B2 (en) 2010-09-08 2014-11-11 Sumitomo Chemical Company, Limited Method for producing pyridazinone compounds and intermediate thereof
US8889877B2 (en) 2010-03-23 2014-11-18 Viiv Healthcare Company Processes for preparing pyridinone carboxylic acid aldehydes
CN104903323A (zh) * 2012-12-27 2015-09-09 日本烟草产业株式会社 取代螺吡啶并[1,2-a]吡嗪衍生物及其作为HIV整合酶抑制剂的医药用途
US9200009B2 (en) 2011-10-12 2015-12-01 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase inhibitory activity
US9216995B2 (en) 2010-04-12 2015-12-22 Shionogi & Co., Ltd. Pyridone derivative having integrase inhibitory activity
US9216996B2 (en) 2012-12-21 2015-12-22 Gilead Sciences, Inc. Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections
WO2016005331A1 (en) * 2014-07-07 2016-01-14 F. Hoffmann-La Roche Ag Pyridopyrazine compounds and their use in the treatment, amelioration or prevention of influenza
US9328119B2 (en) 2013-09-12 2016-05-03 Alios Biopharma, Inc. AZA-pyridone compounds and uses thereof
US9421214B2 (en) 2013-07-12 2016-08-23 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US9522912B2 (en) 2014-12-23 2016-12-20 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US9630978B2 (en) 2015-04-02 2017-04-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US9682084B2 (en) 2014-06-20 2017-06-20 Gilead Sciences, Inc. Crystalline forms of (2R,5S,13AR)-8-hydroxy-7,9,-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
US9708342B2 (en) 2014-06-20 2017-07-18 Gilead Sciences, Inc. Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate
US20180118760A1 (en) 2015-04-28 2018-05-03 Shionogi & Co., Ltd. Substituted polycyclic pyridone derivatives and prodrugs thereof
US9994600B2 (en) 2014-07-02 2018-06-12 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
US10065950B2 (en) 2010-02-26 2018-09-04 Japan Tobacco Inc. Substituted thiazoles as HIV integrase inhibitors
US10208045B2 (en) 2015-03-11 2019-02-19 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
US10449210B2 (en) 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
US10456395B2 (en) 2013-07-12 2019-10-29 Gilead Sciences, Inc. Substituted dipyrido[1,2-a:1′,2′-d]pyrazines for treating viral infections
US10479801B2 (en) 2016-12-02 2019-11-19 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as HIV integrase inhibitors
US10519168B2 (en) 2014-06-20 2019-12-31 Gilead Sciences, Inc. Synthesis of polycyclic-carbamoylpyridone compounds
US11358711B2 (en) 2019-06-20 2022-06-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as HIV integrase inhibitors
US11952374B2 (en) 2020-10-21 2024-04-09 Aligos Therapeutics, Inc. Bicyclic compounds
US11957683B2 (en) 2021-06-18 2024-04-16 Aligos Therapeutics, Inc. Bicyclic compounds
US11970482B2 (en) 2018-01-09 2024-04-30 Ligand Pharmaceuticals Inc. Acetal compounds and therapeutic uses thereof
US12384779B2 (en) 2022-04-20 2025-08-12 Aligos Therapeutics, Inc. Bicyclic compounds

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006232849A (ja) * 2003-08-13 2006-09-07 Japan Tobacco Inc 含窒素縮合環化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
WO2005051300A2 (en) * 2003-11-19 2005-06-09 Array Biopharma Inc. Bicyclic inhibitors of mek and methods of use thereof
US7732616B2 (en) * 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7517994B2 (en) * 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
AU2005220767A1 (en) * 2004-03-09 2005-09-22 Merck & Co., Inc. HIV integrase inhibitors
WO2005092099A1 (en) * 2004-03-09 2005-10-06 Merck & Co., Inc. Hiv integrase inhibitors
JP4705164B2 (ja) 2005-05-02 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｃｖｎｓ３プロテアーゼ阻害剤
EP1967516B1 (en) * 2005-05-18 2009-11-04 Array Biopharma, Inc. 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative diseases
JP2006342115A (ja) * 2005-06-10 2006-12-21 Shionogi & Co Ltd Ｈｉｖインテグラーゼ阻害活性を有する多環性化合物
JP2009502964A (ja) * 2005-07-27 2009-01-29 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを阻害するための抗ウイルス性ホスホン酸結合体
MX2008001588A (es) 2005-08-01 2008-02-19 Merck & Co Inc Inhibidores de proteasa ns3 del vhc.
WO2007039218A1 (en) * 2005-10-04 2007-04-12 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Hiv integrase inhibitors
BRPI0617842A2 (pt) * 2005-10-27 2011-08-09 Shionogi & Co composto ou um sal farmaceuticamente aceitável ou um solvato do mesmo, e, composição farmacêutica
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
US20100216834A1 (en) * 2006-10-18 2010-08-26 Isaacs Richard C A Hiv integrase inhibitors
US8309540B2 (en) 2006-10-24 2012-11-13 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
CA2667146C (en) 2006-10-24 2016-01-19 Merck & Co., Inc. Hcv ns3 protease inhibitors
US8377873B2 (en) 2006-10-24 2013-02-19 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
JP5352464B2 (ja) 2006-10-27 2013-11-27 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｃｖｎｓ３プロテアーゼ阻害剤
BRPI0718161A2 (pt) 2006-10-27 2013-11-26 Merck & Co Inc Composto, composição farmacêutica, e, uso do composto.
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2008075103A1 (en) 2006-12-20 2008-06-26 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Antiviral indoles
AU2007342367B2 (en) 2007-01-05 2012-12-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
US8138191B2 (en) 2007-01-11 2012-03-20 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
JP2010533698A (ja) 2007-07-17 2010-10-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Ｃ型肝炎感染症の治療のための大環状インドール誘導体
JP5433573B2 (ja) 2007-07-19 2014-03-05 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ 抗ウイルス剤としての大環状化合物
US20090291921A1 (en) * 2007-11-20 2009-11-26 Gilead Sciences, Inc. Integrase inhibitors
JP5562255B2 (ja) 2008-01-25 2014-07-30 キメリクス，インコーポレイテッド ウイルス感染を治療する方法
US8461107B2 (en) 2008-04-28 2013-06-11 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
RS53420B (sr) 2008-07-22 2014-12-31 Msd Italia S.R.L. Kombinacije makrocikličnog jedinjenja hinoksalina koje je inhibitor hcv ns3 proteaze sa drugim hcv sredstvima
WO2010011819A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
CN102239172A (zh) * 2008-10-06 2011-11-09 默沙东公司 Hiv整合酶抑制剂
WO2010082050A1 (en) 2009-01-16 2010-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
SI2444400T1 (en) * 2009-06-15 2018-06-29 Shionogi & Co., Ltd. Substituted polycyclic carbamoylpyridone derivative
WO2011014487A1 (en) 2009-07-30 2011-02-03 Merck Sharp & Dohme Corp. Hepatitis c virus ns3 protease inhibitors
SMT201800290T1 (it) 2010-01-27 2018-07-17 Viiv Healthcare Co Terapia antivirale
EP3216789A1 (en) 2010-02-12 2017-09-13 Chimerix, Inc. Methods of treating viral infection
EP3235818A3 (en) 2010-04-01 2018-03-14 Critical Outcome Technologies, Inc. Compounds for the treatment of hiv
JP5553393B2 (ja) 2010-09-24 2014-07-16 塩野義製薬株式会社 置換された多環性カルバモイルピリドン誘導体のプロドラッグ
US9328138B2 (en) 2011-11-15 2016-05-03 Msd Italia S.R.L. HCV NS3 protease inhibitors
WO2014121417A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121416A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121418A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
EP2997033B1 (en) 2013-05-17 2017-11-15 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
WO2014200880A1 (en) 2013-06-13 2014-12-18 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
EP3016935B1 (en) * 2013-07-04 2018-09-05 Hetero Research Foundation Process for the preparation of intermediate of dolutegravir
TN2016000090A1 (en) 2013-09-27 2017-07-05 Merck Sharp & Dohme Substituted quinolizine derivatives useful as hiv integrase inhibitors.
WO2015089847A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
WO2016005330A1 (en) 2014-07-07 2016-01-14 F. Hoffmann-La Roche Ag Dihydropyridopyrazine-1,8-diones and their use in the treatment, amelioration or prevention of viral diseases
JPWO2016027879A1 (ja) 2014-08-22 2017-06-01 塩野義製薬株式会社 インテグラーゼ阻害活性を有する多環性ピリドン誘導体
WO2016090545A1 (en) * 2014-12-09 2016-06-16 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrate inhibitors
CN113004304B (zh) 2015-04-28 2022-03-18 盐野义制药株式会社 经取代的多环性吡啶酮衍生物及其前药
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
US10548910B2 (en) 2015-11-17 2020-02-04 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors
WO2017106071A1 (en) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors
KR102084109B1 (ko) 2015-12-15 2020-03-03 시오노기세야쿠 가부시키가이샤 캡 의존적 엔도뉴클레아제 저해제 및 항인플루엔자 약을 조합하는 것을 특징으로 하는 인플루엔자 치료용 의약
WO2017113288A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
US10858366B2 (en) 2016-03-08 2020-12-08 Novartis Ag Tricyclic compounds useful to treat orthomyxovirus infections
US10759814B2 (en) 2016-08-10 2020-09-01 Shionogi & Co., Ltd. Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
EP3548031B1 (en) 2016-12-02 2023-07-19 Merck Sharp & Dohme LLC Tricyclic heterocycle compounds useful as hiv integrase inhibitors
EP3573984A4 (en) 2017-01-26 2020-07-29 Merck Sharp & Dohme Corp. USEFUL SUBSTITUTE QUINOLIZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS
CN118878544A (zh) 2018-02-28 2024-11-01 诺华股份有限公司 作为正粘病毒复制抑制剂用于治疗流感的化合物
EP3784241A4 (en) * 2018-04-27 2022-01-19 Merck Sharp & Dohme Corp. TETRACYCLIC HETEROCYCLENIC COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS
WO2019230858A1 (ja) 2018-05-31 2019-12-05 塩野義製薬株式会社 多環性カルバモイルピリドン誘導体
US11453669B2 (en) 2018-05-31 2022-09-27 Shionogi & Co., Ltd. Polycyclic pyridone derivative
TWI880167B (zh) * 2018-05-31 2025-04-11 日商鹽野義製藥股份有限公司 多環性吡啶并三衍生物
WO2020004443A1 (ja) * 2018-06-27 2020-01-02 国立大学法人北海道大学 多環性カルバモイルピリドン誘導体を含有するアレナウイルス増殖阻害剤
TWI838401B (zh) 2018-09-12 2024-04-11 瑞士商諾華公司 抗病毒性吡啶并吡𠯤二酮化合物
JP7495395B2 (ja) 2018-09-20 2024-06-04 ブラックスミス メディシンズ，インク． 抗菌性化合物
EP4034537A1 (en) 2019-09-26 2022-08-03 Novartis AG Antiviral pyrazolopyridinone compounds
US20230059640A1 (en) 2019-11-28 2023-02-23 Shionogi & Co., Ltd. Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent
AU2022357226A1 (en) 2021-09-28 2024-05-02 Blacksmith Medicines, Inc. Lpxc inhibitors and uses thereof
WO2024151855A1 (en) * 2023-01-13 2024-07-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicyclic carbamoyl pyridone-based integrase strand transfer inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5519016A (en) * 1992-05-27 1996-05-21 Ube Industries, Ltd. Aryl group- or aromatic heterocyclic group-substituted aminoquinolone derivatives and anti-HIV agent

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2502281B2 (ja) 1985-02-25 1996-05-29 キヤノン株式会社 情報信号処理装置
CA1317298C (en) 1987-03-03 1993-05-04 Upjohn Company (The) Antibiotic sulfonylaminocarbonyl activated .beta.-lactams
JP2993316B2 (ja) * 1992-05-27 1999-12-20 宇部興産株式会社 アリール基又は複素芳香環基置換アミノキノロン誘導体及びエイズ治療剤
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
US6770666B2 (en) * 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
WO2001095905A1 (fr) 2000-06-14 2001-12-20 Shionogi & Co., Ltd. Inhibiteur d'enzymes possedant deux ions metal divalents en tant que centres actifs
MXPA02012405A (es) 2000-06-16 2003-06-06 Bristol Myers Squibb Co Inhibidores de integrasa del virus de inmunodeficiencia humana.
JP2002155084A (ja) * 2000-09-11 2002-05-28 Takeda Chem Ind Ltd ３環性複素環化合物、その製造法およびその用途
WO2002022574A1 (en) 2000-09-11 2002-03-21 Takeda Chemical Industries, Ltd. Tricyclic heterocyclic compound, process for producing the same, and use thereof
ATE345129T1 (de) * 2000-10-12 2006-12-15 Merck & Co Inc Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
JP2004513134A (ja) 2000-10-12 2004-04-30 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルケトン類
ATE430745T1 (de) 2000-10-12 2009-05-15 Merck & Co Inc Aza- und polyaza naphthalenyl karboxamide als inhibitoren der hiv-integrase
JP4287649B2 (ja) 2000-10-12 2009-07-01 メルク エンド カムパニー インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類
JP2002293745A (ja) 2001-03-29 2002-10-09 St Marianna Univ School Of Medicine 慢性関節リウマチ治療剤
AR035543A1 (es) * 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
BR0211750A (pt) 2001-08-10 2004-10-13 Shionogi & Co Agente antiviral
WO2003016266A1 (fr) 2001-08-16 2003-02-27 Japan Tobacco Inc. Composes $g(b)-cetoamides et leur utilisation medicinale
FR2830863B1 (fr) 2001-10-12 2004-01-30 Bioalliance Pharma Derives de quinoleine, procede de synthese, et medicaments renfermant ces derives
CN102229605B (zh) 2001-10-26 2015-01-14 Msd意大利有限公司 关于hiv整合酶的n-取代的羟基嘧啶酮甲酰胺抑制剂
ATE355064T1 (de) 2001-10-26 2006-03-15 Angeletti P Ist Richerche Bio Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
JP4497347B2 (ja) 2001-12-05 2010-07-07 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する誘導体
CA2472372C (en) * 2002-01-17 2010-08-17 Melissa Egbertson Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors
EP1549315A4 (en) 2002-09-11 2007-05-23 Merck & Co Inc DIHYDROXYPYRIDOPYRAZINE-1,6-DION COMPOUNDS AS HIV INTEGRASE INHIBITORS
DE10337191A1 (de) * 2003-08-13 2005-03-17 Bayer Healthcare Ag Neue Verwendung von Chinolon-Antibiotika
US7247649B2 (en) * 2003-08-13 2007-07-24 Hoffmann-La Roche Inc. Oxazoles, their manufacture and use as pharmaceutical agents
CL2004002050A1 (es) * 2003-08-13 2005-06-03 Pharmacia Corp Sa Organizada B Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
NZ545159A (en) * 2003-08-13 2009-03-31 Smith Howard J & Ass Pty Ltd Method of treating viral infections
AU2005220767A1 (en) 2004-03-09 2005-09-22 Merck & Co., Inc. HIV integrase inhibitors
WO2005092099A1 (en) 2004-03-09 2005-10-06 Merck & Co., Inc. Hiv integrase inhibitors
CA2558026C (en) 2004-03-09 2010-12-14 Merck & Co., Inc. Hiv integrase inhibitors
AU2005221864A1 (en) 2004-03-09 2005-09-22 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa HIV integrase inhibitors
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
WO2006066414A1 (en) 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
EP1852434B1 (en) * 2005-02-21 2011-07-13 Shionogi Co., Ltd. Bicyclic carbamoylpyridone derivative having hiv integrase inhibiting activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5519016A (en) * 1992-05-27 1996-05-21 Ube Industries, Ltd. Aryl group- or aromatic heterocyclic group-substituted aminoquinolone derivatives and anti-HIV agent
US5688791A (en) * 1992-05-27 1997-11-18 Ube Industries, Ltd. Aryl group-or aromatic heterocyclic group-substituted aminoquinolone derivatives and anti-hiv agent

Cited By (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070161639A1 (en) * 2004-03-09 2007-07-12 Philip Jones Hiv integrase inhibitors
US7598264B2 (en) 2004-03-09 2009-10-06 Merck & Co., Inc. HIV integrase inhibitors
US20090099168A1 (en) * 2004-03-09 2009-04-16 Monica Donghi HIV Integrase inhibitors
US20070179196A1 (en) * 2004-03-09 2007-08-02 Wei Han Hiv integrase inhibitors
US20050261322A1 (en) * 2004-05-18 2005-11-24 Naidu B N HIV integrase inhibitors
US7115601B2 (en) 2004-05-18 2006-10-03 Bristol-Myers Squibb Company HIV integrase inhibitors
US8633219B2 (en) 2004-05-21 2014-01-21 Japan Tobacco Inc. Combination therapy
US20050288326A1 (en) * 2004-05-21 2005-12-29 Yuji Matsuzaki Combination therapy
US20070249687A1 (en) * 2004-09-15 2007-10-25 Hiroshi Yoshida Carbamoylpyridone Derivatives Having Inhibitory Activity Against Hiv Integrase
US7550463B2 (en) 2004-09-15 2009-06-23 Shionogi & Co., Ltd. Carbamoylpyridone derivatives having inhibitory activity against HIV integrase
US7745459B2 (en) 2004-09-21 2010-06-29 Japan Tobacco Inc. Quinolizinone compound and use thereof as HIV integrase inhibitor
US20060084665A1 (en) * 2004-09-21 2006-04-20 Motohide Satoh Quinolizinone compound and use thereof as HIV integrase inhibitor
US20080161271A1 (en) * 2005-02-21 2008-07-03 Hiroshi Yoshida Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
US7858788B2 (en) 2005-02-21 2010-12-28 Shionogi & Co., Ltd. Bicyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
US20090253681A1 (en) * 2005-03-31 2009-10-08 Vincenzo Summa HIV Integrase Inhibitors
US7981879B2 (en) 2005-03-31 2011-07-19 Instituto di Ricerchi di Biologia Molecolare P. Angeletti S.p.A. HIV integrase inhibitors
EP3284520A1 (en) * 2005-04-28 2018-02-21 VIIV Healthcare Company Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
WO2006116764A1 (en) * 2005-04-28 2006-11-02 Smithkline Beecham Corporation Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
US9051337B2 (en) 2005-04-28 2015-06-09 Shionogi & Co., Ltd. Substituted 10-hydroxy-9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydro-1h-pyrido[1,2-a]pyrrolo[1′,2′:3,4]imidazo[1,2-d]pyrazine-8-carboxamides
US9273065B2 (en) 2005-04-28 2016-03-01 Shionogi & Co., Ltd. Substituted pyrido[1',2':4,5]pyrazino[1,2-a]pyrimidines as HIV integrase inhibitors
US8778943B2 (en) 2005-04-28 2014-07-15 Shionogi & Co., Ltd. Substituted 10-hydroxy-9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydro-1h-pyrido[1,2-α]pyrrolo[1′,2′:3,4]imidazo[1,2-d]pyrazine-8-carboxamides
EA014162B1 (ru) * 2005-04-28 2010-10-29 Смитклайн Бичем Корпорейшн Полициклическое карбамоилпиридоновое производное, обладающее ингибиторной активностью в отношении интегразы вич
AU2006239177B2 (en) * 2005-04-28 2011-10-20 Shionogi & Co., Ltd. Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
AU2006239177B8 (en) * 2005-04-28 2012-02-16 Shionogi & Co., Ltd. Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
US8129385B2 (en) 2005-04-28 2012-03-06 Shionogi & Co., Ltd. Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
US11267823B2 (en) 2005-04-28 2022-03-08 Shionogi & Co., Ltd. Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1′,2′:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having HIV integrase inhibitory activity
EP2465580A1 (en) * 2005-04-28 2012-06-20 Glaxosmithkline LLC Polycyclic carbamoylpyridone derivatives having hiv integrase inhibitory activity
US8410103B2 (en) 2005-04-28 2013-04-02 Shionogi & Co., Ltd. (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent
US10927129B2 (en) 2005-04-28 2021-02-23 Shinogi & Co., Ltd. N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity
NO339525B1 (no) * 2005-04-28 2016-12-27 Shionogi & Co Polycyklisk karbamoylderivat, farmasøytisk sammensetning omfattende denne samt denne forbindelsen og sammensetningener omfattende denne for behandling av sykdom.
NO340111B1 (no) * 2005-04-28 2017-03-13 Shionogi & Co Polysyklisk karbamoylderivat, farmasøytisk sammensetning omfattende samme samt slike forbindelser for anvendelse i medisinsk terapi
AU2006244424B2 (en) * 2005-05-10 2011-09-22 Merck Sharp & Dohme Corp. HIV integrase inhibitors
US20090018162A1 (en) * 2006-02-01 2009-01-15 Yuji Matsuzaki Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection
US20090306054A1 (en) * 2006-05-16 2009-12-10 Gilead Sciences ,Inc. Integrase inhibitors
US9707246B2 (en) 2008-07-25 2017-07-18 Shionogi & Co., Ltd. Substituted (3S,11AR)-N-[(2,4-difluorophenyl)methyl]-6-oxy-3-methyl-5,7-dioxo-2,3,5,7,11,11A-hexahydro[1,3]oxazolo[3,2-A]pyrido[1,2-D]pyrazine-8-carboxamides as HIV agents
US8940912B2 (en) 2008-07-25 2015-01-27 Viiv Healthcare Company 4-oxo-3-[(phenylmethyl)oxy]-4H-pyran-2-carboxylic acid
US8580967B2 (en) 2008-07-25 2013-11-12 Shionogi & Co., Ltd. Methyl 3-(benzyloxy)-1-(2,2-dihydroxyethyl)-4-oxo-1,4-dihydropyridine-2-carboxylate and processes for the preparation thereof
US8765965B2 (en) 2008-07-25 2014-07-01 Shionogi & Co., Ltd. 1-(2,3-dihydroxypropyl)-4-oxo-3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylic acid of the formula P-6 and/or methyl 1-(2,3-dihydroxypropyl)-4-oxo-3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylate of the formula P-7
US20110183940A1 (en) * 2008-07-25 2011-07-28 Brian Alvin Johns Chemical compounds
US9133216B2 (en) 2008-07-25 2015-09-15 Shionogi & Co., Ltd. (3S,11aR)-6-[(phenylmethyl)oxy]-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-dione of the formula P-9 and/or (3S,11aR)-6-[(phenymethyl)oxy]-8-bromo-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-dione of the formula P-10
WO2010011818A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
US9012650B2 (en) 2008-07-25 2015-04-21 Shionogi & Co., Ltd. Substituted (3S, 11aR)-N-[(2,4-difluorophenyl)methyl]-6-oxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamides of formula (I) useful as HIV agents
US8981129B2 (en) 2008-07-25 2015-03-17 Shionogi & Co., Ltd. 2-(2-hydroxy-2-phenylethyl)-3-[(phenylmethyl)oxy]-4H-pyran-4-one of the formula P-3 and/or 2-[(E)-2-phenylethenyl]-3-[(phenylmethyl)oxy]-4H-Pyran-4-one of the formula P-4
US9365587B2 (en) 2008-12-11 2016-06-14 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
US8552187B2 (en) 2008-12-11 2013-10-08 Shionogi & Co., Ltd. Processes and intermediates for carbamoylpyridone HIV integrase inhibitors
US9242986B2 (en) 2008-12-11 2016-01-26 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
US8754214B2 (en) 2008-12-11 2014-06-17 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
JP2012511573A (ja) * 2008-12-11 2012-05-24 塩野義製薬株式会社 カルバモイルピリドンｈｉｖインテグラーゼ阻害剤及びそれらの中間体の合成
US8669362B2 (en) 2008-12-11 2014-03-11 Shiongi & Co., Ltd. Processes and Intermediates for carbamoylpyridone HIV integrase inhibitors
US8624023B2 (en) 2008-12-11 2014-01-07 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
CN104151234B (zh) * 2009-03-26 2017-04-12 盐野义制药株式会社 吡喃酮和吡啶酮衍生物的制备方法
CN104230795B (zh) * 2009-03-26 2017-09-26 盐野义制药株式会社 吡喃酮和吡啶酮衍生物的制备方法
EP3109235A1 (en) * 2009-03-26 2016-12-28 Shionogi & Co., Ltd Method of producing pyridone derivatives
EP2412709A4 (en) * 2009-03-26 2013-11-27 Shionogi & Co PROCESS FOR THE PREPARATION OF PYRONO AND PYRIDONE DERIVATIVES
US9505783B2 (en) 2009-03-26 2016-11-29 Shionogi & Co., Ltd. Method of producing pyrone and pyridone derivatives
CN104230795A (zh) * 2009-03-26 2014-12-24 盐野义制药株式会社 吡喃酮和吡啶酮衍生物的制备方法
CN104151234A (zh) * 2009-03-26 2014-11-19 盐野义制药株式会社 吡喃酮和吡啶酮衍生物的制备方法
US9260453B2 (en) 2009-03-26 2016-02-16 Shionogi & Co., Ltd. Method for producing pyrone and pyridone derivatives
US8865907B2 (en) 2009-03-26 2014-10-21 Shionogi & Co., Ltd. Method of producing pyrone and pyridone derivatives
US10065950B2 (en) 2010-02-26 2018-09-04 Japan Tobacco Inc. Substituted thiazoles as HIV integrase inhibitors
US9643981B2 (en) 2010-03-23 2017-05-09 Viiv Healthcare Company Process for preparing (4R,12aS)-N-(2,4-difluorobenzyl)-7-methoxy-4-methyl-6,8-dioxo-3,4,6,8,12,12A-hexahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
US10647728B2 (en) 2010-03-23 2020-05-12 Viiv Healthcare Company Process for preparing (3S,11aR)-6-methoxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-Hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxylic acid
US10654871B2 (en) 2010-03-23 2020-05-19 Viiv Healthcare Company Process for preparing (3S,11aR)-N-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
US9938296B2 (en) 2010-03-23 2018-04-10 Viiv Healthcare Company Process for preparing (4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
US8889877B2 (en) 2010-03-23 2014-11-18 Viiv Healthcare Company Processes for preparing pyridinone carboxylic acid aldehydes
US10654870B2 (en) 2010-03-23 2020-05-19 Viiv Healthcare Company Process for preparing substituted pyridinones as intermediates in the preparation of polycyclic carbamoylpyridone derivatives
US10174051B2 (en) 2010-03-23 2019-01-08 Viiv Healthcare Company Substituted pyridinones as intermediates in the preparation of polycyclic carbamoylpyridone derivatives
US10233196B2 (en) 2010-03-23 2019-03-19 Viiv Healthcare Company Process for preparing substituted pyridinones as intermediates in the preparation of polycyclic carbamoylpyridone derivatives
US9120817B2 (en) 2010-03-23 2015-09-01 Viiv Healthcare Company Process for preparing (4R,12aS)-7-methoxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1′ ,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylic acid
US9216995B2 (en) 2010-04-12 2015-12-22 Shionogi & Co., Ltd. Pyridone derivative having integrase inhibitory activity
US8884010B2 (en) 2010-09-08 2014-11-11 Sumitomo Chemical Company, Limited Method for producing pyridazinone compounds and intermediate thereof
US9040709B2 (en) 2010-09-08 2015-05-26 Sumitomo Chemical Company, Limited Method for producing pyridazinone compounds and intermediate thereof
US9200009B2 (en) 2011-10-12 2015-12-01 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase inhibitory activity
WO2014099586A1 (en) * 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
US9714243B2 (en) 2012-12-17 2017-07-25 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as HIV integrase inhibitors
US10035809B2 (en) 2012-12-21 2018-07-31 Gilead Sciences, Inc. Substituted 2,3,4,5,7,9,13,13a-octahydro-1,5-methanopyrido[1′,2′:4,5]pyrazino[1,2-a][1,3]diazepines and methods for treating viral infections
US9663528B2 (en) 2012-12-21 2017-05-30 Gilead Sciences, Inc. Substituted 1,2,3,4,6,8,12,12a-octahydro-1,4-methanodipyrido[1,2-a:1',2'-d]pyrazines and methods for treating viral infections
US9732092B2 (en) 2012-12-21 2017-08-15 Gilead Sciences, Inc. Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections
US11548901B2 (en) 2012-12-21 2023-01-10 Gilead Sciences, Inc. Substituted 1,4-methanopyrido[1′,2′:4,5]pyrazino[1,2-a]pyrimidines for treating viral infections
US9216996B2 (en) 2012-12-21 2015-12-22 Gilead Sciences, Inc. Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections
US10689399B2 (en) 2012-12-21 2020-06-23 Gilead Sciences, Inc. Substituted 3,4,5,6,8,10,14,14a-octahydro-2h-2,6-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazocines and methods for treating viral infections
US10087178B2 (en) 2012-12-27 2018-10-02 Japan Tobacco Inc. Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as HIV integrase inhibitor
CN104903323A (zh) * 2012-12-27 2015-09-09 日本烟草产业株式会社 取代螺吡啶并[1,2-a]吡嗪衍生物及其作为HIV整合酶抑制剂的医药用途
US9493479B2 (en) 2013-04-16 2016-11-15 Merck Sharp & Dohme Corp. Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors
WO2014172188A2 (en) 2013-04-16 2014-10-23 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
WO2014172188A3 (en) * 2013-04-16 2015-10-29 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
US10456395B2 (en) 2013-07-12 2019-10-29 Gilead Sciences, Inc. Substituted dipyrido[1,2-a:1′,2′-d]pyrazines for treating viral infections
US11883397B2 (en) 2013-07-12 2024-01-30 Gilead Sciences, Inc. Substituted pyrido[1,2-a]pyrrolo[1,2-d]pyrazines for treating viral infections
US11213523B2 (en) 2013-07-12 2022-01-04 Gilead Sciences, Inc. Substituted pyrido[1,2-a]pyrrolo[1,2-d]pyrazines for treating viral infections
US10668064B2 (en) 2013-07-12 2020-06-02 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US9700554B2 (en) 2013-07-12 2017-07-11 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US9421214B2 (en) 2013-07-12 2016-08-23 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US10980805B2 (en) 2013-09-12 2021-04-20 Janssen Biopharma, Inc. Aza-pyridone compounds and uses thereof
US9328119B2 (en) 2013-09-12 2016-05-03 Alios Biopharma, Inc. AZA-pyridone compounds and uses thereof
US10251882B2 (en) 2013-09-12 2019-04-09 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
US10702523B2 (en) 2013-09-12 2020-07-07 Janssen Biopharma, Inc. AZA-pyridone compounds and uses thereof
US11278559B2 (en) 2014-02-13 2022-03-22 Ligand Pharmaceuticals Incorporated Prodrug compounds and their uses
US10449210B2 (en) 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
US9708342B2 (en) 2014-06-20 2017-07-18 Gilead Sciences, Inc. Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate
US9682084B2 (en) 2014-06-20 2017-06-20 Gilead Sciences, Inc. Crystalline forms of (2R,5S,13AR)-8-hydroxy-7,9,-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
US10385067B2 (en) 2014-06-20 2019-08-20 Gilead Sciences, Inc. Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate
US10098886B2 (en) 2014-06-20 2018-10-16 Gilead Sciences, Inc. Crystalline forms of (2R,5S,13AR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13A- octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-B] [1,3] oxazepine-10-carboxamide
US11202780B2 (en) 2014-06-20 2021-12-21 Gilead Sciences, Inc. Crystalline forms of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
US10519168B2 (en) 2014-06-20 2019-12-31 Gilead Sciences, Inc. Synthesis of polycyclic-carbamoylpyridone compounds
US10975096B2 (en) 2014-06-20 2021-04-13 Gilead Sciences, Inc. Synthesis of polycyclic-carbamoylpyridone compounds
US9994600B2 (en) 2014-07-02 2018-06-12 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
US10150788B2 (en) 2014-07-02 2018-12-11 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses thereof
WO2016005331A1 (en) * 2014-07-07 2016-01-14 F. Hoffmann-La Roche Ag Pyridopyrazine compounds and their use in the treatment, amelioration or prevention of influenza
US10646486B2 (en) 2014-12-23 2020-05-12 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US9795602B2 (en) 2014-12-23 2017-10-24 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US9522912B2 (en) 2014-12-23 2016-12-20 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US10208045B2 (en) 2015-03-11 2019-02-19 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
US9630978B2 (en) 2015-04-02 2017-04-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US10392406B2 (en) 2015-04-28 2019-08-27 Shionogi & Co., Ltd. Substituted polycyclic pyridone derivatives and prodrugs thereof
US10633397B2 (en) 2015-04-28 2020-04-28 Shionogi & Co., Ltd. Substituted polycyclic pyridone derivatives and prodrugs thereof
US20180118760A1 (en) 2015-04-28 2018-05-03 Shionogi & Co., Ltd. Substituted polycyclic pyridone derivatives and prodrugs thereof
US10479801B2 (en) 2016-12-02 2019-11-19 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as HIV integrase inhibitors
US10829499B2 (en) 2016-12-02 2020-11-10 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as HIV integrase inhibitors
US11970482B2 (en) 2018-01-09 2024-04-30 Ligand Pharmaceuticals Inc. Acetal compounds and therapeutic uses thereof
US11358711B2 (en) 2019-06-20 2022-06-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as HIV integrase inhibitors
US11952374B2 (en) 2020-10-21 2024-04-09 Aligos Therapeutics, Inc. Bicyclic compounds
US11957683B2 (en) 2021-06-18 2024-04-16 Aligos Therapeutics, Inc. Bicyclic compounds
US12384779B2 (en) 2022-04-20 2025-08-12 Aligos Therapeutics, Inc. Bicyclic compounds

Also Published As

Publication number Publication date
DE602004017108D1 (de) 2008-11-27
EP1544199A1 (en) 2005-06-22
SI1544199T1 (sl) 2009-04-30
EP2042502A1 (en) 2009-04-01
US20080161311A1 (en) 2008-07-03
JPWO2005016927A1 (ja) 2006-10-12
AR045367A1 (es) 2005-10-26
DK1544199T3 (da) 2009-01-12
EP1544199B1 (en) 2008-10-15
PT1544199E (pt) 2008-12-03
ATE411315T1 (de) 2008-10-15
PE20050361A1 (es) 2005-06-27
CA2577239A1 (en) 2005-02-24
EP1544199A4 (en) 2006-07-26
ES2315700T3 (es) 2009-04-01
JP3814631B2 (ja) 2006-08-30
TW200510425A (en) 2005-03-16
US20060052361A1 (en) 2006-03-09
US7211572B2 (en) 2007-05-01
WO2005016927A1 (ja) 2005-02-24
CL2004002061A1 (es) 2005-06-03

Similar Documents

Publication Publication Date Title
US7211572B2 (en) Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
JP4252797B2 (ja) Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類
JP5765965B2 (ja) １，３，４，８−テトラヒドロ−２Ｈ−ピリド［１，２−ａ］ピラジン誘導体及びそのＨＩＶインテグラーゼ阻害剤としての利用
EP1937639B1 (en) Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4 (cyp3a4)
MXPA06015032A (es) Inhibidores de cinasa hetrociclicos fusionados.
EA019027B1 (ru) Производные флуорена, содержащие их композиции и применение
US20080045537A1 (en) Chemical Compounds
KR20040018281A (ko) 포진 바이러스 감염의 예방 및 치료를 위한 이미다조[1，２－α]피리딘 유도체
BG107284A (bg) Заместени пиролопиридинонови производни полезни като инхибитори на фосфодиестераза
JP2006504728A (ja) ピラソロピリジン誘導体系治療用化合物
EP2331541B1 (en) Indolizine inhibitors of leukotriene production
JP4166991B2 (ja) ピリドピリミジンまたはナフチリジン誘導体
KR20210013154A (ko) 헤테로축합된 피리돈 화합물 및 idh 억제제로서의 이의 용도
KR20020058091A (ko) 신규한 1,8-나프티리딘-2(1ｈ)-온 유도체
CN114206856A (zh) 抗疟疾的六氢嘧啶类似物
US20070142365A1 (en) Naphthyridine integrase inhibitors
JP2006232849A (ja) 含窒素縮合環化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
HK1128031A (en) Nitrogen-containing fused ring compound and use thereof as hiv integrase inhibitor
HK1079512A (en) Nitrogenous condensed-ring compound and use thereof as hiv integrase inhibitor
JP2004115450A (ja) 医薬組成物
JP2004043416A (ja) β−ケトアミド化合物及びその医薬用途
US20240150346A1 (en) Class of heteroaromatic compound, preparation method therefor and use thereof
JP2009511463A (ja) Ｈｉｖインテグラーゼ酵素の阻害剤
HK1179615A (en) 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor
HK1120506B (en) Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4 (cyp3a4)

Legal Events

Date Code Title Description
AS Assignment

Owner name: JAPAN TOBACCO INC., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MIYAZAKI, SUSUMU;KATOH, SUSUMU;ADACHI, KAORU;AND OTHERS;REEL/FRAME:016635/0344;SIGNING DATES FROM 20050711 TO 20050726

STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING PUBLICATION PROCESS